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1. Introduction 
 
 
1.1. Renal diseases 
 
Renal diseases represent a global public health problem that affects every year a large number 
of patients worldwide. Indeed, due to their essential role in the in homeostasis maintenance, 
kidneys are exposed to numerous insults of different nature, resulting in a large variety of renal 
injuries that can affect the lifestyle of patients to varying extents. Therefore, an early stage 
diagnosis of kidney damage is essential to be able to intervene immediately and efficiently. 
Diagnosis of kidney diseases is possible by checking markers of renal failure in blood and urine. 
Glomerular filtration rate (GFR), which describes how efficient is the renal filtration, is 
considered the best indicator of renal function and any changes of this parameter may reflect a 
pathological state 1.  However, since early kidney diseases usually do not have any symptoms, 
patients often have a delayed diagnosis, which results in a poor prognosis. An early detection 
and treatment of acute kidney injury (AKI) is extremely important to prevent its possible 
progression to chronic kidney disease or end-stage renal disease (ESRD) 2. Regarding possible 
treatments, the only available options to date for ESRD are dialysis and/or renal transplantation, 
which are invasive for the patients and highly expensive for the public health care system 2. It 
is therefore clear that alternative treatments for renal diseases are urgently needed.  
 
In the next paragraphs, we will discuss about drug-induced kidney injuries (1.2) with focus on 
the antineoplastic drug cisplatin (1.3) and we will present stem cell therapy (1.4) as a possible 
treatment for cisplatin-induced kidney injury.  
 
1.2. Drug-induced nephrotoxicity  
 
Due to the kidneys’ key role in plasma clearance, renal cells are directly exposed to all 
possible molecules present in the bloodstream, including drugs, some of which are known to 
have a nephrotoxic effect. Indeed, many different compounds can affect kidneys at different 
levels and with different modes of action. As shown in Figure 1, drugs can exert their 
nephrotoxicity by altering the kidney hemodynamics, obstructing excretory function or 
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directly harming renal cells 3-5. The effects can be observable in terms of functional 
alterations, such as glomerular and/or tubular dysfunction, impaired renal endocrine function, 
inadequate blood pressure control and  histopathological lesions 5, 6. Although it is difficult to 
determine the real incidence, it has been estimated that approximately 20% of AKI in adult 
populations is attributed to drug-induced nephrotoxicity 7-10. 
 
 
 
 
Figure 1 Common nephrotoxins and their site and mechanism of injury. ACE-I: angiotensin-converting enzyme 
inhibitors; ARB: angiotensin II receptor blockers; NSAID: nonsteroideal anti-inflammatory drugs 4 
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Among different classes of drugs, chemotherapeutics represent a well-known example of 
nephrotoxic agents 11. Indeed, the nephrotoxic side effect of chemotherapeutics is a limiting 
factor in cancer treatment, especially in patients where pre-existing and/or maybe subclinical 
renal injuries are present. Additionally, patients undergoing chemotherapy can develop several 
health complications throughout life and require, therefore, a constant follow-up. In this 
scenario, it is easy to understand that the diagnosis of an early stage kidney failure is essential 
for a good prognosis of the patients.  
 
 
1.3. Chemotherapeutic-induced nephrotoxicity: cisplatin 
 
Cis-diamminedichloroplatinum-(II), commonly called cisplatin, is a well-known and widely 
used chemotherapeutic drug. Synthetized for the first time at the beginning of the 19th century, 
its antineoplastic properties were discovered and demonstrated only one century later 12-14.  In 
the 1970s, cisplatin was introduced in clinics 15 and approved by the U.S. Food and Drug 
Administration, becoming commercially available as Platinol® (Bristol-Myers Squibb) 16.  
 
Cisplatin shows a remarkable and incomparable potency against certain types of neoplasms, 
such as testicular cancer, for the treatment of which shows 90% efficacy 17. According to the 
NIH National Cancer Institute database, cisplatin is nowadays used, alone or in combination 
with other drugs, to not only cure testicular malignancy but also for the treatment of ovarian, 
cervical, bladder, non-small cell lung and head and neck cancer, among others. Although 
cisplatin is nowadays considered as a gold standard for the treatment of solid tumors and 
hematological malignancies, its well-known side effects represent a big limitation for its 
application.  
 
Cisplatin belongs to the ` not specific-targeted´ class of antineoplastic drugs: once intravenously 
(iv) administrated, it destroys cancerous cells by interfering with their DNA replication. Indeed, 
once accumulated inside the cells, cisplatin is converted into a potent toxin capable of triggering 
cell damage 18. Cisplatin is a neutral inorganic compound consisting of a central ion of platinum 
linked to two chloride ions and two ammonia molecules. Due to the typical intracellular low 
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concentration of chloride ions, one or both cisplatin chloride ligands are replaced by water 
molecules generating a positively charged compound 19 (Figure 2).  
 
Figure 2 Mechanisms of cellular uptake and toxicity of cisplatin 19 
 
 
This new compound is now able to react with the nucleophilic molecules of the cells, including 
DNA, RNA and proteins. One of the key mechanisms involved in cisplatin cytotoxicity, is 
oxidative stress, which is known to mainly affect mitochondria 20. It has been suggested that 
cisplatin-induced excessive reactive oxygen species can induce cell death via apoptosis through 
both the extrinsic and intrinsic pathways 21, necrosis 22 and even autophagy23 
 
However, due to its not cell-specific action, cisplatin can exert a cytotoxic effect also on healthy 
tissues, at the renal, gastrointestinal, hepatic, hematological, cardiovascular and neurological 
level 24, 25. As widely reported in literature, kidneys are highly affected by cisplatin and the 
severity of nephrotoxicity is dose- and time-dependent and shows a cumulative effect 26, 27. It 
has been shown that up to 35% of patients who received a single dose of cisplatin experience 
impairment of renal function characterized by a decrease in GFR and an increase in serum 
creatinine and urea nitrogen 28-30. The induced damage is often reversible, but a significant 
proportion of the affected patients exhibit a worsening of renal function and are developing a 
progressive loss of renal function 30. To understand the mechanisms behind its nephrotoxic 
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effect, it is necessary to elucidate what happens when this drug reaches the nephrons (Figure 
3). 
 
 
Figure 3 Renal drug excretion 31 
 
 
After administrated, cisplatin is mainly eliminated through the kidneys by glomerular filtration 
and secretion, with no evidence of tubular reabsorption 30. Secretion of cisplatin is an active 
process mediated by the organic cationic transporter isoform 2, which is highly expressed in 
the basolateral membrane of proximal tubular cells 32, 33. The presence of this transporter 
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explains why cisplatin accumulates in the kidneys in a more pronounced manner than in any 
other organ. This selective accumulation in the proximal tubular cells is so pronounced that a 
non-toxic amount of cisplatin in the blood can result in renal damage 34. Once in the proximal 
tubular cells, cisplatin leads to the activation of signaling pathways inducing injury, cell death 
and inflammatory response. All this translates into a loss of renal function and the occurrence 
of AKI. The typical renal histopathological changes induced by cisplatin include necrosis and 
degeneration of tubular epithelial cells, loss of brush border, dilation of tubular lumen, 
cytoplasmic vacuolization and infiltration of lymphocytes and macrophages 30, 35. 
 
In order to overcome cisplatin-induced nephrotoxicity during chemotherapy, cisplatin was also 
tested in combination with renoprotective agents 36. An alternative strategy was developing 
cisplatin analogues with the same anti-tumor efficacy and lesser toxic effects. However, only 
few platinum-based chemotherapeutic agents, such as carboplatin and oxaliplatin, have 
obtained approval after clinical trials, but even so, the use of cisplatin has not been fully 
replaced 37, 38. 
 
In animal experiments, cisplatin has been used for decades to create models of kidney injury. 
Especially in rodents, cisplatin-induced nephrotoxicity represents a simple and widely used 
model that has many similarities to human cisplatin nephrotoxic effect and that can therefore 
be used for assessing the putative therapeutic potential of different treatments 39.  
 
 
1.4 .   Stem-cell therapy for the treatment of cisplatin-induced kidney injury 
 
Within the last decades, the application of stem cells for the treatment of several diseases has 
become relevant. Exploiting their differentiation potential, stem cells are currently tested in a 
variety of pathologic conditions, including the field of nephrology. In cisplatin-induced 
nephrotoxicity models, different sources and doses of stem cells, applied with different timing 
and via different administration routes, have been tested and promising results in terms of 
survival rate, renal function and morphology have been achieved 40.  
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Noteworthy, both allogeneic and xenogeneic cells have been tested and, nowadays, an 
increasing number of studies involve the application of human stem cells in animal models, 
rising several debates and concerns. Undoubtedly, considering a possible translation to the 
clinical field, testing human cells in animals seems to be a reasonable approach.  
Stem cells are known to have immune-modulatory properties, thanks to which they are able to 
escape and suppress the host immune system, making them suitable for transplantation across 
species 41. However, after xenogeneic stem cells administration, some studies reported both 
humoral and cellular responses 42. Additionally, in a recent study conducted by Lohan et al., 
immunomodulation of human stem cells were ineffective in a rat model of corneal 
transplantation because of interspecies incompatibilities. Indeed, the authors claim that human 
stem cells cannot be properly stimulated in a xenogeneic environment and therefore they cannot 
exert their immune modulatory action 43. It is clear that the pronounced discordances observed 
in this area need to be clarified with further experiments.  
 
Studying the mechanisms of action through which stem cells exert their therapeutic potential 
on a pathologic condition, scientists agree more and more on a possible paracrine action of the 
cells rather than their homing and engraftment in a particular organ 44, 45. For this reason, the 
attention has been lately focused on the secretome, assuming that the therapeutic potential of 
stem cells is not due to the cells themselves but it is more ascribed to what they release into the 
medium where they grow 46. Based on this finding, the use of conditioned medium derived from 
stem cells has become an alternative to the use of cell infusion, which is an important alternative 
approach when considering the risk/benefit ratio. However, besides the positive results 
achieved 47, there is a study that demonstrates that different sources of CM do not ameliorate 
the condition of animals suffering kidney failure 48. Once more, discrepancies need to be 
clarified.  
 
In this controversial scenario, it seems that one possible observation is that the putative healing 
effects of stem cells and conditioned medium strictly vary based on cell source, dose, timing 
and severity of the kidney disease.  
 
In a recent study, Schatton et al. identified in human dermis a particular non-hematopoietic cell 
subset that shows immune-regulatory functions similar to stem cells 49. These dermal immune-
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regulatory cells (DIRCs) are characterized by the expression of the ATP-binding cassette 
member B5 (ABCB5) peptide on their membrane and represent a unique dermal subpopulation. 
According to the authors, ABCB5 positive (ABCB5+) DIRCs may lead to promising results in 
cellular immunotherapy applications.  
To the best of our knowledge, ABCB5+ cells and derived conditioned medium have not been 
applied for the treatment of nephrotoxicity yet. In the light of this, we decided to test whether 
ABCB5+ cells and derived conditioned medium may exert a therapeutic effect in the treatment 
of cisplatin-induced kidney failure.  
Preliminary results of an ongoing study has demonstrated that local injection of ABCB5+ cells 
around a wound accelerates the healing process by triggering the resident macrophage 
polarization from a M1 pro-inflammatory to a M2 anti-inflammatory phenotype via paracrine 
release of IL-1RA (Ticeba, personal communication). Therefore, when ABCB5+ cells are co-
cultured with macrophages, the healing effect produced by the two cell populations together is 
enhanced. We decided to test whether the conditioned medium derived from the 
aforementioned co-culture could ameliorate the conditions of animals suffering kidney injury. 
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2. Aims of the study 
 
 
The aim of this study was to test whether human ABCB5+ cells and different derived 
conditioned media can exert a therapeutic effect in an animal model of kidney nephropathy.  
 
First, a stable model of cisplatin-induced kidney injury in immunocompetent Sprague Dawley 
(SD) rats was established. The onset and progression of renal damage was evaluated through 
periodically measuring metabolic, plasmatic and urinary parameters and performing 
transcutaneous assessment of renal function.  
The established model was then used to test the therapeutic potential of human ABCB5+ cells. 
This particular population of DIRCs was purified from skin of healthy individuals of different 
sex, age and nationality by Ticeba-RHEACELL and was delivered as a ready-to-use solution. 
In order to overcome a possible trapping of the cells in the lungs and a subsequent pulmonary 
embolism, besides the classical intravenous (iv) administration route, ABCB5+ cells were also 
intraperitoneally (ip) injected and the outcomes were compared. 
 
Based on the latest findings regarding the secretome and the possible application of stem cell 
derived conditioned medium as an alternative approach, we decided to test also the therapeutic 
potential of ABCB5+ cell derived conditioned medium (CM). 
Additionally, exploiting the immune-modulatory effects that ABCB5+ have on macrophages, 
conditioned medium derived from a co-culture of ABCB5+ and macrophages was also tested 
in our cisplatin-induced nephrotoxicity model. In this case, the co-culture was stimulated with 
lipopolysaccharide (LPS) and interferon-gamma (IFNγ), factors that are known to trigger 
macrophages polarization into the M2 anti-inflammatory phenotype. This particular 
conditioned medium was addressed as coCM+. 
Lastly, to test a possible effect of LPS and IFN-γ on stem cells only, ABCB5+ cells were 
cultured and stimulated without macrophages and the derived conditioned medium, referred as 
CM+, was also tested in our model.  
All the media were iv administered to the animals and were delivered by Ticeba-RHEACELL 
as a ready-to-use solution. 
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In summary, a stable model of cisplatin-induced kidney injury was established in 
immunocompetent SD rats for testing the following treatments: 
- ABCB5+ cells iv and ip administrated; 
- conditioned media iv administrated and derived from: 
o ABCB5+ cells (CM) 
o ABCB5+ cells co-cultured with Macrophages and stimulated with LPS and IFN-
γ (coCM+) 
o ABCB5+ cells stimulated with LPS and IFN-γ (CM+) 
 
The therapeutic potential of the aforementioned treatments was evaluated by analyzing: 
- Urine and blood parameters; 
- Metabolic parameters; 
- Transcutaneous assessment of renal function; 
- Histological evaluation; 
- mRNA and miRNA expression profiling. 
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3. Animals, materials and methods 
 
 
3.1. Animal experiments 
 
All experiments were conducted in accordance with the German Animal Protection Law and 
approved by the local authority (Regierungspräsidium Nordbaden, Karlsruhe Germany in 
agreement with EU guideline 2010/63/EU. Male SD rats (Janvier- Labs), about 200 g were used 
in all the experiments. The establishment of kidney failure (section 3.5.) and the assessment of 
the therapeutic potential of ABCB5+ cells and CM (section 3.7.) involved 24 and 49 animals 
respectively. 73 animals in total were used. Before the start of any experiment, animals were 
acclimatized for 1 week. The first 2 days following cisplatin administration, animals were 
housed in pairs in individually ventilated cages to avoid cisplatin metabolites to be spread out.  
 
 
3.2.  Evaluation days 
 
The animals’ state of health was periodically checked and the evaluation days were organized 
as described: 16 hours before the evaluation, animals were placed into metabolic cages. Before 
and after this period, the following parameters were recorded: body weight (BW), diuresis, food 
and drink intake. On evaluation day, urine samples were collected early in the morning and 
thereafter, blood sampling was performed under anesthesia. Samples were processed as 
described in section 3.3. Animals were left to recover from the anesthesia for at least one hour. 
Afterwards, transcutaneous renal function was assessed as described in section 3.4. 
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3.3.  Blood and urine collection 
 
Blood samples were collected via ophthalmic venous plexus (orbital sinus) under anesthesia 
(5% isoflurane at 3 L/min airflow) in lithium-heparinized tubes using capillaries for blood 
collection. After centrifugation (5 minutes at 2000 g, 4°C) plasma was collected in 1.5 ml tubes 
and stored at -20°C until further analyses. Urine was collected overnight in individual metabolic 
cages for a period of 16 hours. Animals had free access to water and food during this time. At 
the end of each collection period, the urine volume was recorded and samples were centrifuged 
(78 g, 5 minutes) to remove precipitates. Centrifuged urine aliquots were placed in 2 ml tubes 
and stored at -20°C until further analyses. Plasma and urine chemical parameters were 
determined by using the Cobas c311 analyzer (Roche Diagnostics GmbH, Mannheim, 
Germany). Urinary albumin was determined by ELISA assay and osmolarity was analyzed 
using an osmometer (2020 Multi-Sample Osmometer, Advanced Instruments Inc., Norwood, 
MA). 
 
 
3.4. Transcutaneous assessment of renal function 
 
The transcutaneous assessment of renal function was performed by using a transdermal device 
(MediBeacon GmbH, Mannheim, Germany). The optical part of the device consists of two 
light-emitting diodes, with an emission in the near infrared region (excitation: 706nm, emission: 
790nm), and a photodiode detecting the fluorescent light. Energy is supplied by a small lithium 
polymer rechargeable battery with a voltage of 3.7V and capacity of 50 mAh.  The recorded 
digital data are stored in the internal memory of the device and are then downloaded onto a PC 
for the analysis 50-53. To perform the transcutaneous measurement of renal function, the device 
and the connected battery were attached to a specifically designed double-sided adhesive patch 
and then fixed on the shaved back of the animal. The animal received a dose of 15mg/100 g 
BW of ABZWCY-HPβCD (stock solution 160 mg/ml in Deltajonin) via tail-vein injection, and 
its emitted fluorescent signal was recorded by the device 54. Shaving, fixation of the device and 
dose administration were performed under short isoflurane anesthesia (5% isoflurane at 3 L/min 
air flow, decreasing to 2% isoflurane at 1.5 L/min air flow). The measurement was performed 
for at least 2 hours, during which the animal was completely awake and freely moving. The 
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recorded data represented the excretion curves of ABZWCY-HPβCD. To determine the half-
life excretion of the administered ABZWCY-HPβCD, a 3-compartment model was applied 
using the open source freely-available software ‘GFRmeasure’ 
(https://www.mathworks.com/products/compiler/matlab-runtime.html). 
 
 
3.5. Development of cisplatin-induced nephropathy model in SD 
rats 
 
Kidney failure was induced by cisplatin administration. Cisplatin was purchased as a ready-to-
use solution (TEVA, 1mg/ml solution) and it was administered via ip route under short 
isoflurane anesthesia (5% isoflurane at 3 L/min air flow, decreasing to 2% isoflurane at 1.5 
L/min air flow). To induce kidney damage, a single dose of 7 mg/kg BW was chosen. Control 
animals received the same volume of sterile saline. 24 animals were used for the whole 
experiment (control n=3; cisplatin n=21). Six animals from the cisplatin group were excluded 
from the analysis because they died or were sacrificed before the end of the experiment. 
Therefore, 18 animals were finally included in the analysis (control n=3; cisplatin n=15, Table 
1). 
 
Animals Control Cisplatin
Total 3 21
Dead before day 15 6
Perfused on day 15 3 15
 
Table 1 Number of animals involved in the establishment of the cisplatin-induced nephrotoxicity model. Animals 
perfused on day 15 were included in the analysis 
 
 
The day of the first cisplatin/saline administration was considered as day 0. Evaluation days 
were performed 3 days before the start of the experiment (baseline), and 2, 7 and 14 days after 
cisplatin/saline administration. Animals were sacrificed on day 15 by perfusion (0.9% saline 
heparin 5 IU/mL pH=7 for 3min at 280mbar, PFA 4% for 3min at 230mbar) under anesthesia 
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(Rompun 2% 5mg/Kg BW and Ketamin 10%, 100mg/Kg BW). The fresh left kidney was 
collected before perfusion and immediately snap-frozen in liquid nitrogen for subsequent 
mRNA extraction (section 3.10.). Other organs (right kidney, spleen, liver, pancreas, intestine, 
heart, lungs) were collected after perfusion and processed for subsequent histology and 
immunofluorescence analyses (section 3.9.). The experimental set-up is described in Figure 4. 
 
 
 
Figure 4 Experimental set-up for the establishment of cisplatin-induced nephropathy model in SD rats 
 
 
 
3.6.  ABCB5+ cells and conditioned media 
 
Ready to use ABCB5+ cells and conditioned media were delivered from Ticeba-RHEACELL 
GmbH & Co. (Heidelberg, Germany). Conditioned media were obtained by collecting the 
supernatant of the following cell cultures: 
- CM: ABCB5+ cell culture; 
- CM+: ABCB5+ stimulated cell culture; 
- M+: human monocyte cell line THP-1 cultured with PMA to induce macrophage 
differentiation. After stimulation, macrophages polarize to M1 pro-inflammatory 
macrophages; 
- coCM+: ABCB5+ co-cultured with THP-1 derived macrophages. After stimulation and 
in presence of ABCB5+ cells, THP-1 derived macrophages polarize to M2 anti-
inflammatory macrophages.  
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Stimulation consisted of IFN-γ and LPS for promoting macrophage polarization. Cells were 
stimulated with 50IU/ml IFN-γ on the seeding day (first day) and with 50IU/ml IFN-γ + 
20ng/ml LPS on the day after. The third day, conditioned media were harvested and 
immediately frozen and stored at -20C until injection into the animals or subsequent analysis. 
An overview of what has been just described is shown in Figure 5.  
 
 
 
Figure 5 Conditioned media obtained by collecting the supernatant of ABCB5+ cells and/or macrophages with or 
without stimuli. IFN-γ: Interferon-gamma; LPS: lipopolysaccharide 
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3.7. Assessment of the therapeutic potential of human ABCB5+ cells 
and conditioned media in a cisplatin-induced nephropathy model 
 
To assess the therapeutic potential of human ABCB5+ cells and conditioned media, the same 
experimental set-up used for the establishment of the cisplatin-induced nephrotoxicity model 
was used. Treatments were administrated on day 3. 
More in detail, after baseline evaluation, on day 0 all animals received a single ip dose of 
cisplatin (7mg/kg BW). On day 2, blood and urine parameters were analyzed and the 
transcutaneous measurement of renal function was assessed in order to confirm whether the 
renal damage was properly induced. Thereafter, rats were randomly allocated to different 
groups according to the treatment received on day 3: 
1) Group ivABCB5+: 2x106 ABCB5+ cells iv administrated; 
2) Group ipABCB5+:  2x106 ABCB5+ cells ip administrated; 
3) Group CM: 0.5ml of CM iv administrated; 
4) Group CM+: 0.5ml of CM+ iv administrated; 
5) Group coCM+: 0.5ml of coCM+ iv administrated; 
6) Group vehicle: 0.5ml of fresh medium (RPMI1640 + L-Glutamine) iv administrated as 
a positive control.  
The animals´ health-status was evaluated on day 7 and 14, and the animals were sacrificed on 
day 15 as previously described in section 3.5. The experimental set-up is shown in Figure 6.  
 
 
 
Figure 6 Experimental set-up for the assessment of the therapeutic potential of human ABCB5+ cells and 
conditioned media in a cisplatin-induced nephropathy model 
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49 animals were involved in the experiment (iv ABCB5+ n=12; ip ABCB5+ n=12; CM n=4; 
CM+ n=4, coCM n=12; vehicle n=5). Six animals (ip ABCB5+ n=1; CM n=1; CM+ n=1, coCM 
n=1; vehicle n=2) were excluded from the analysis because they died or were sacrificed before 
the end of the experiment. Therefore, 43 animals were finally included in the analysis (iv 
ABCB5+ n=12; ip ABCB5+ n=11; CM n=3; CM+ n=3, coCM n=11; vehicle n=3, Table 2). 
 
Animals ABCB5 ip ABCB5 iv CM CM+ coCM+ Vehicle 
Total 12 12 4 4 12 5
Dead before day 15 1 1 1 2
Perfused on day 15 11 12 3 3 11 3
 
Table 2 Number of animals involved in the assessment of the therapeutic potential of human ABCB5+ cells and 
conditioned media in the cisplatin-induced nephropathy model. Animals perfused on day 15 were included in the 
analysis 
 
 
3.8.  Statistical analysis 
 
All statistical calculations regarding blood, urine and metabolic parameters as well as renal 
function values were performed using SAS JMP 13.0.0 (SAS Institute, Cary, NC, USA). 
Kruskal-Wallis tests were applied to evaluate the changes induced by cisplatin administration 
in the development of the model and the effect of the different therapies applied on injured 
animals. For all tests, nominal p-values <0.05 (*) or <0.005 (**) were considered as statistically 
significant. 
 
 
3.9.  Histology collection, staining, analysis and microscopy 
 
On the day of the sacrifice, organs (right kidney, spleen, liver, pancreas, intestine, heart, lungs) 
were collected after perfusion and stored in 4% PFA for 24h. Fixed tissues were embedded in 
paraffin, cut (3μm) and stained with hematoxylin and eosin (H&E). H&E slices were used to 
detect morphological changes induced by cisplatin and full organ images were acquired using 
Axio Scan.Z1 microscope (ZEISS).  
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3.10.  RNA Isolation 
 
For gene expression analysis, frozen left kidney samples obtained from sacrificed animals were 
used. Total RNA was extracted by using the RNeasy mini kit (Qiagen) following the 
manufacturer's instructions. The mRNA purity and integrity was tested by capillary 
electrophoresis on an Agilent 2100 bioanalyzer (Agilent) and high quality was confirmed. The 
isolated RNA was used for gene expression analysis.  
 
 
3.11.  Affymetrix GeneChips gene expression analysis and 
bioinformatics evaluation 
 
Gene expression profiling was performed using arrays of human RatGene-2_0-st-type from 
Affymetrix. From the RNA, biotinylated antisense cDNA was prepared according to the 
Affymetrix standard labelling protocol by using the GeneChip WT Plus Reagent Kit 
(Affymetrix, Santa Clara, USA) and the  GeneChip Hybridization, Wash and Stain Kit 
(Affymetrix, Santa Clara, USA). The obtained cDNA was first hybridized on the chip with a 
GeneChip Hybridization oven 640, then dyed in the GeneChip Fluidics Station 450 and 
thereafter scanned with a GeneChip Scanner 3000. All of the equipment used was from the 
Affymetrix-Company (Affymetrix, High Wycombe, UK).  
For array annotation, the Custom CDF Version 21 with ENTREZ based gene definitions was 
used (Dai et. al, 2005). The raw fluorescence intensity values were normalized applying 
quantile normalization and RMA background correction. For identification of differentially 
expressed genes, OneWay-ANOVA was performed using the software package SAS JMP10 
Genomics, version 6, from SAS (SAS Institute, Cary, NC, USA). A false positive rate of α= 
0.05 with FDR correction was taken as the level of significance. 
Gene Set Enrichment Analysis (GSEA) was performed by using the software R v3.4.0 (R Core 
Team 2017) and RStudio: Integrated development environment for R (RStudio Boston, MA, 
USA). Pathways were obtained from Kyoto Encyclopedia of Genes and Genomes database 
(KEGG, http://www.genome.jp/kegg) version September 2018. 
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3.12.  RNAseq gene and miRNAs expression and bioinformatics 
evaluation 
 
New generation sequencing (NGS) gene expression profiling was performed with RNA 
sequencing (RNAseq) technology by BGI Tech Solutions Co. (Hong Kong) with BGISEQ-500 
method. RNAseq data were analyzed and aligned by using RBioconducor and Rsubread 
software respectively. For annotation, the ENTREZ-based software package 
TxDb.Hsapiens.UCSC.hg19.knownGene was used and differential gene expression analysis 
was performed by a DESeq2 package. A false positive rate of α= 0.05 with FDR correction was 
taken as the level of significance. GSEA was performed by using the KEGG database version 
September 2018. 
RNAseq technology also detects differentially expressed miRNA precursors. For miRNAs 
analysis, a false positive rate of α= 0.05 with FDR correction was taken as the level of 
significance. Putative target genes of differentially expressed miRNAs were predicted with the 
miRWalk program with a cutoff of binding p value=1 55. Putative target genes were compared 
with the differentially expressed genes found in the gene expression profiling. For functional 
interpretation of selected genes, the web-based online bioinformatics resource DAVID v6.8 
(Database for Annotation, Visualization and Integrated Discovery) was used and BP-GO 
analysis was performed 56, 57.  
 
 
3.13.  Cytokines assay 
 
Simultaneous detection of 12 cytokines (IL2, IL4, IL5, IL6, IL10, IL12, IL13, IL17A, IFNγ, 
TNFα, G-CSF, TGFβ1) in different conditioned media was assessed with the human 
Th1/Th2/Th17 cytokine Multi-Analyte ELISArray Kit (Qiagen) by following the 
manufacturer's instructions. Samples from 3 different donors were evaluated and the assay was 
repeated twice independently. Due to the kit range, CM and CM+ were tested undiluted, while 
coCM+ and M+ were diluted 10 times. Results were obtained by using the infinite 200 PRO 
NanoQuant Microplate Readers (TECAN).  
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4. Results 
 
 
4.1.  Development and characterization of a cisplatin-induced 
nephrotoxicity model in SD rats 
 
Cisplatin-induced nephrotoxicity model was established as described in section 3.5.  
Briefly, at the beginning of the experiment (day 0), a single intraperitoneal dose of cisplatin (7 
mg/kg BW) was administrated to SD rats in order to induce renal injury. For monitoring the 
animal’s  health state and for characterizing the induced damage, 3 days before (baseline) and 
2, 7 and 14 days after cisplatin administration blood and urine were sampled for biochemical 
analyses, transcutaneous assessment of renal function was assessed and metabolic parameters 
were recorded. Kruskal-Wallis each paired comparison test of cisplatin-treated animals vs 
controls was applied and nominal p-values <0.05 (*) or <0.005 (**) were considered as 
statistically significant.  
15 days after cisplatin administration, fresh left kidney was collected for gene expression 
analysis, while the other organs were collected after animal perfusion for histological 
evaluation. 
 
 
4.1.1. Cisplatin effect on plasma parameters  
 
Blood sampling was performed as described in section 3.3. Plasma biochemical results are 
summarized in Table 3. 
 
Parameter Group Baseline Day 2 Day 7 Day 14 
Creatinine 
(mg/dl) 
Control 0.23 ± 0.0 0.27 ± 0.0 0.28 ± 0.0 0.30 ± 0.0 
Cisplatin 0.26 ± 0.0 0.45 ± 0.0** 2.13 ± 1.5 ** 0.83 ± 0.2* 
Urea 
 (mg/dl) 
Control 29.8 ± 6.7 33.30 ± 9.2 34.53 ± 2.2 33.80 ± 4.1 
Cisplatin 35.36 ± 4.4 67.17 ± 4.1* 258.70 ± 195.9** 83.23 ± 30.5* 
Glucose 
(mg/dl) 
Control 153.66 ± 6.1 161.33 ± 4.6 154.33 ± 8.9 153.33 ± 8.3 
Cisplatin 149.06 ± 7.8 158.66 ± 18.2 160.33 ± 13.1 142.53 ± 6.9 
Protein 
(mg/dl) 
Control 55.66 ± 1.5 59.33 ± 2.3 59.00 ± 2.0 58.33 ± 1.5 
Cisplatin 55.53 ± 1.8 60.26 ± 2.1 55.66 ± 2.9 56.26 ± 3.1 
Cholesterol 
(mg/dl) 
Control 97.66 ± 28.4 100.00 ± 28.2 88.33 ±18.4 87.66 ± 13.0 
Cisplatin 96.00 ± 12.5 140.20 ± 21.5* 113.20 ± 24.3 117.93 ± 15.7* 
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Triglycerides 
(mg/dl) 
Control 90.00 ± 34.6 136.00 ± 26.2 121.66 ± 39.8 108.66 ± 30.4 
Cisplatin 94.40 ± 26.5 73.33 ± 27.0* 130.00 ± 37.8 127.33 ± 38.8 
AST 
(U/l) 
Control 48.3 ± 11.2 67.00 ± 17.5 54.00 ± 19.5 55.00 ± 5.2 
Cisplatin 52.8 ± 11.5 39.92 ± 6.7* 61.93 ± 35.8 51.20 ± 20.8 
ALT 
(U/l) 
Control 103.00 ± 11.9 92.33 ± 2.8 92.33 ± 14.0 100.00 ± 26.8 
Cisplatin 100.53 ± 5.3 104.46 ± 12.7 97.60 ±18.5 91.13 ± 14.2 
GGT 
(U/l) 
Control 3.00 ± 0.0 3.00 ± 0.0 3.00 ± 0.4 3.00 ± 0.0 
Cisplatin 3.00 ± 0.0 3.66 ± 0.9 3.26 ± 0.1 3.00 ± 0.0 
GLDH 
(U/l) 
Control 8.22 ± 0.8 7.80 ± 0.1 7.68 ± 1.2 8.31 ± 2.2 
Cisplatin 8.60 ± 1.3 9.13 ± 2.1 19.2 ± 4.5 4.91 ± 1.2 
Na 
(mmol/l) 
Control 133.66 ± 6.4 141.00 ± 1.0 136.66 ± 7.5 143.50 ± 2.1 
Cisplatin 139.53 ± 4.5 140.13 ± 1.5 138.00 ± 4.2 139.36 ± 2.7 
Ca 
(mmol/l) 
Control 2.71 ± 0.0 2.80 ± 0.1 2.72 ± 0.0 2.71 ± 0.0 
Cisplatin 2.71 ± 0.0 2.73 ± 0.1* 2.75 ± 0.2* 2.84  ± 0.0* 
K 
(mmol/l) 
Control 4.72 ± 0.5 4.97 ± 0.3 4.41 ± 0.4 4.45 ± 0.6 
Cisplatin 4.95 ± 0.3 4.19 ± 0.3* 4.77 ± 0.5 5.55 ± 0.6 
PO4 
(mmol/l) 
Control 2.55 ± 0.3 2.49 ± 0.1 2.31 ± 0.2 2.48 ± 0.1 
Cisplatin 2.75 ± 0.1 2.47 ± 0.2 2.20 ± 0.9 1.41 ± 0.5** 
Table 3 Changes in plasma biochemistry in control (n= 3) and cisplatin-treated (n= 15) groups. Data are shown as 
mean ± SD. Values significantly different from control are indicated as *p< 0.05 and **p< 0.005 
 
 
Already 2 days after cisplatin administration, both creatinine and urea increased by 1.6-fold and 
2-fold respectively (creatinine p<0.005, urea p<0.05) compared to the corresponding controls 
and remained higher until day 14 (p<0.05). Particularly on day 7, we observed an increase of 
7.6-fold for creatinine and 7.5-fold for urea (p<0.005) (Figure 7). 
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Figure 7 Effect of cisplatin administration in plasma creatinine and urea concentration. Control group n=3 in blue, 
cisplatin-treated group n=15 in red. Statistically significant differences are indicated as *p< 0.05 and **p< 0.005 
 
 
Cisplatin also induced a 1.4-fold increase of plasma cholesterol already on day 2, which 
remained higher until day 14 (p<0.05) with respect to the control group. Additionally, the 
triglycerides levels halved on day 2 (p<0.05) in the cisplatin-treated animals, and then increased 
in the following days, by reaching a 1.2-fold increase on day 14 (Figure 8) 
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Figure 8 Effect of cisplatin administration in plasma cholesterol and triglycerides concentration. Control group 
n=3 in blue, cisplatin-treated group n=15 in red. Statistically significant differences are indicated as *p< 0.05 
 
 
Plasma electrolyte levels were also affected by cisplatin.  Indeed, hypokalemia on day 2 
(p<0.05) and hypophosphatemia on day 14 (p<0.005) was recorded in the treated animals 
compared to the controls (Figure 9). Hypercalcemia was also observed from day 7 onwards 
(p<0.05). In contrast, sodium level remained stable. 
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Figure 9 Effect of cisplatin administration in plasma potassium, phosphate and calcium concentration. Control 
group n=3 in blue, cisplatin-treated group n=15 in red. Statistically significant differences are indicated as *p< 
0.05 and **p< 0.005 
 
 
Plasma levels of liver enzymes were also measured. A reduction by half in AST levels was 
recorded on day 2 (p<0.05) in the treated animals compared to the controls. The AST value 
returned to basal levels on day 7. Additionally, GDHL levels increased by 2.5-fold on day 7 
(not statistically significant) and halved on day 14. No differences in ALT and GGT levels were 
observed (Figure 10).  
 4. Results  -25- 
 
 
 
 
 
 
Figure 10 Effect of cisplatin administration in plasma AST and GLDH level. Control group n=3 in blue, cisplatin-
treated group n=15 in red. Statistically significant differences are indicated as *p< 0.05 
 
 
No statistically significant differences among the groups were found for plasma levels of 
glucose and proteins. 
 
 
 
4.1.2. Cisplatin effect on urine parameters 
 
Urine was collected overnight during 16 h as described in section 3.3. All urine parameters 
were normalized to the volume of urine produced in 16h. Urinary biochemical results are 
summarized in Table 4. 
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Parameter Group Baseline Day 2 Day 7 Day 14 
Creatinine  
(mg/16h) 
Control 6.76 ± 1.6 8.53 ± 0.4 9.86 ± 1.1 11.13 ± 1.2 
Cisplatin 7.24 ± 1.4 8.19 ± 2.3 7.10 ± 2.2 7.94 ± 1.8* 
Urea 
  (mg/16h) 
Control 477.39 ± 94.2 588.06 ± 116.9 661.29 ± 27.0 686.27 ± 40.5 
Cisplatin 431.60 ± 82.5 496.33 ± 129.7 616.61 ± 220.5 588.45 ± 82.1* 
Glucose  
(mg/16h) 
Control 3.75 ± 0.9 3.32 ± 0.2 3.68 ± 0.8 3.76 ± 0.5 
Cisplatin 3.33 ± 1.1 10.81 ± 6.9 63.37 ± 42.3* 100.76 ± 87.5* 
Protein  
(mg/16h) 
Control 6.76 ± 2.4 9.59 ± 2.5 11.46 ± 1.9 10.68 ± 2.7 
Cisplatin 8.12 ± 3.2 12.9 ± 1.1 8.85 ± 3.1 12.17 ± 4.6 
Albumin 
(mg/16h) 
Control 0.28 ± 0.1 0.18 ± 0.0 0.22 ± 0.0 0.23 ± 0.0 
Cisplatin 0.21 ± 0.1 2.71 ± 1.3** 4.92 ± 2.3** 4.24 ± 2.8** 
Na 
(mmol/16h) 
Control 1.82 ± 0.1 1.87 ± 0.1 2.05 ± 0.1 2.43 ± 0.2 
Cisplatin 2.08 ± 0.4 1.53 ± 1.0 1.71 ± 0.9 2.20 ± 0.7 
Ca 
(mmol/16h) 
Control 0.03 ± 0.0 0.03 ± 0.0 0.03 ± 0.0 0.03 ± 0.0 
Cisplatin 0.02 ± 0.0 0.03 ± 0.0 0.08 ± 0.0 0.18 ± 0.0* 
K 
(mmol/16h) 
Control 4.02 ± 0.2 4.42 ± 0.4 4.72 ± 0.3 4.46 ± 0.3 
Cisplatin 3.80 ± 0.5 2.52 ± 0.6** 2.62 ± 1.4 3.88 ± 1.4 
PO4 
(mmol/16h) 
Control 0.16 ± 0.0 0.05 ± 0.0 0.04 ± 0.0 0.07 ± 0.0 
Cisplatin 0.13 ± 0.0 0.59 ± 0.3* 0.19 ± 0.1 0.05 ± 0.0 
Table 4 Changes in urine biochemistry in control (n= 3) and cisplatin-treated (n= 15) groups. Values were 
normalized to the volume of urine produced in 16 hours.  Data are shown as means ± SD. Values significantly 
different from control are indicated as *p< 0.05 and **p< 0.005 
 
 
 
Cisplatin administration induced a significant albuminuria from day 2 onwards with respect to 
the corresponding controls (p<0.005). Specifically, albumin concentration increased by 15, 22 
and 18-fold on day 2, 7 and 14 respectively. Additionally, cisplatin-treated animals also 
developed progressive glycosuria. Glucose levels in treated animals increased by 17.2-fold on 
day 7 (p<0.05) until 26.8-fold on day 14 (p<0.05) (Figure 11). 
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Figure 11 Albuminuria and glycosuria induced by cisplatin administration. Control group n=3 in blue, cisplatin-
treated group n=15 in red. Values were normalized to the volume of urine produced in 16 hours. Statistically 
significant differences are indicated as *p< 0.05 and **p<0.005 
 
 
 
Concerning the urineelectrolytes, hypokalemia (p<0.005) and hyperphosphatiuria (p<0.05) 
were observed from day 2 in the treated animals compared to the time-matched control. Both 
parameters returned to basic levels on day 14. Additionally, calcium concentration significantly 
increased in cisplatin-treated animals on day 14 (p<0.05) (Figure 12).   
In contrast, sodium level in the urine remained stable in both groups. 
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Figure 12 Effect of cisplatin administration in urine potassium phosphate and calcium concentrations. Control 
group n=3 in blue, cisplatin-treated group n=15 in red. Values were normalized to the volume of urine produced 
in 16 hours. Statistically significant differences are indicated as *p< 0.05 and **p< 0.005 
 
 
No statistically significant differences were found among the groups for urine levels of urea 
and protein.  
 
 
 
4.1.3. Cisplatin effect on renal function 
 
The transcutaneous assessment of renal function was performed as described in section 3.4. As 
shown in Table 5 and Figure 13, ABZWCY-HPβCD half-life significantly increased by 1.8-
fold already 2 days after cisplatin administration (p<0.05) and remained high until the end of 
the experiment, increasing by 2.1-fold on day 14. The observed changes in ABZWCY-HPβCD 
elimination curves represent the loss in renal function. 
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Parameter Group Baseline Day 2 Day 7 Day 14 
Half-life  
(min) 
Control 39.80 ± 0.0 39.93 ± 1.2 33.10 ± 2.9 32.30 ± 2.1 
Cisplatin 38.67 ± 7.8 69.64 ± 10.3 * 68.01 ± 19.0 82.73 ± 38.3* 
Table 5 Changes in ABZWCY-HPβCD half-life. Control group n=3 in blue, cisplatin-treated group n=15 in red. 
Data are shown as means ± SD. Values significantly different from control are indicated as *p< 0.05 and **p< 
0.005 
 
 
 
Figure 13 Transcutaneous assessment of renal function. Effect of cisplatin administration on ABZWCY-HPβCD 
half-life. Control group n=3 in blue, cisplatin-treated group n=15 in red. Data are shown as means ± SD. 
Statistically significant differences are indicated as *p< 0.05  
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4.1.4. Cisplatin effect on body weight, diuresis, food and water intake 
 
Before and after being in metabolic cages for 16 hours, changes in diuresis, BW, food and water 
intake were recorded. The values are summarized in Table 6 
 
Parameter Group Baseline Day 2 Day 7 Day 14 
Diuresis 
(ml/16h)  
Control 10.93 ± 1.9 10.5 ± 1.1 11.86 ± 1.1 14.50 ± 2.3 
Cisplatin 11.68 ± 2.0 16.1 ± 10.8 36.03 ± 10.0* 37.19 ± 2.4* 
Water intake 
  (ml/16h) 
Control 30.83 ± 1.8 34.26 ± 2.0 33.90 ± 2.9 29.30 ± 5.9 
Cisplatin 26.38 ± 2.9* 23.38 ± 16.8 56.35 ± 18.7* 55.75 ± 12.5* 
Body weight   
(g) 
Control 360.33 ± 41.3 409.83 ± 22.0 435.33 ± 12.5 455.33 ± 18.0 
Cisplatin 366.53 ± 33.5 395.46 ± 37.1 376.80 ± 49.8* 386.26 ± 53.3* 
Food intake 
  (g/16h) 
Control 20.96 ± 5.2 26.26 ± 2.6 24.86 ± 1.4 22.43 ± 4.6 
Cisplatin 19.54 ± 3.1 8.93 ± 5.8** 15.86 ± 5.3* 21.38 ± 3.0 
Table 6 Changes in body weight, diuresis, food and water intake before and after metabolic cage allocation in 
control (n=3) and cisplatin-treated (n=15) groups. Data are shown as means ± SD. Values significantly different 
from control are indicated as *p< 0.05 and **p< 0.005 
 
 
Diuresis visibly increased on day 7 and 14 by 3 and 2.5-fold respectively (p<0.05) in the 
cisplatin group compared to the control one. Accordingly, the water intake also increased by 
1.6-fold on day 7 and significantly by 1.9-fold on day 14 (p<0.05) (Figure 14) 
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Figure 14 Effect of cisplatin on diuresis and water intake.  Control group n=3 in blue, cisplatin-treated group n=15 
in red. Data are shown as means ± SD. Statistically significant differences are indicated as *p< 0.05 
 
 
Already 2 days after cisplatin administration, animals ate less and stopped gaining weight 
(p<0.05). On day 14, the loss of weight gain became evident. After the first week, the treated 
animals restarted eating, reaching the basal food intake values on day 14. In contrast, in 
control animals the food intake remained quite stable while the BW gain progressively 
increased over time with respect to baseline values (Figure 15) 
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Figure 15 Effect of cisplatin on body weight and food intake. Control group n=3 in blue, cisplatin-treated group 
n=15 in red. Data are shown as means ± SD. Statistically significant differences are indicated as *p< 0.05 and 
**p< 0.005 
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4.1.5. Cisplatin effect on renal morphology 
 
H&E kidney sections have revealed profound changes in the renal cytoarchitecture due to 
cisplatin administration (Figure 16 and Figure 17). The cortical region was the most affected 
area. Proximal tubules appeared highly degenerated with tubular cells detached from the basal 
membrane. Proximal tubule lumen appeared dilated (black asterisks) and was often filled with 
protein casts or dregs of extruded necrotic cells (green arrows and asterisks). Around the 
tubules, fibrotic tissue deposition and inflammatory cell infiltration were detected (yellow 
arrows). Due to the kidney's self-recovery capacity, flat regenerating distal tubular cells were 
also present. These histological observations indicate that the kidney injury model was 
successfully established. 
 
 
Figure 16 Effect of cisplatin on renal morphology. Whole kidney scan of a control (A) and a cisplatin-treated rat 
(B) and corresponding magnification of the corticomedullary region (C, D) showing the altered cytoarchitecture 
due to the induced damage. Black asterisks: proximal tubular dilatation; green arrows: protein casts; yellow arrows: 
new fibrotic tissue and inflammatory cell infiltrates. H&E staining. Images acquired with Axio Scan.Z1 
microscope (ZEISS). 
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Figure 17 Effect of cisplatin on renal morphology. Magnification of the kidney cortical region of a cisplatin treated 
animal. Black asterisks: proximal tubular dilatation; green arrows: protein casts; yellow arrows: new fibrotic tissue 
and inflammatory cell infiltrates. H&E staining. Images acquired with Axio Scan.Z1 microscope (ZEISS). 
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4.2. Therapeutic effect of ABCB5+ cells and conditioned media in 
cisplatin-induced nephrotoxicity model in SD rats 
 
Three days after cisplatin administration, the therapeutic potential of ABCB5+ cells and 
different conditioned media was tested. The following experimental groups were created: 
ivABCB5+, ipABCB5+, CM, CM+, coCM and vehicle. For monitoring the state of health of 
the animals and for characterizing any possible effect due to the treatments, blood and urine 
were sampled for biochemical analyses, renal function was assessed and metabolic parameters 
were recorded 3 days before (baseline) and  2, 7 and 14 days after cisplatin administration. 
Kruskal-Wallis each paired comparison test of treated animals vs cisplatin-treated animals was 
applied and nominal p-values <0.05 (*) or <0.005 (**) were considered as statistically 
significant. 15 days after cisplatin administration, fresh left kidney was collected for gene 
expression analysis, while the other organs were collected after animal perfusion for 
histological evaluation.  
 
 
 
4.2.1. ABCB5+ cells/conditioned media effect on plasma parameters 
 
Plasma sampling was performed as described in section 3.3. Plasma biochemical results are 
summarized in Table 7.  
 
Parameter Group Baseline Day 2 Day 7 Day 14 
 
 
Creatinine 
(mg/dl) 
Cisplatin 0.26 ± 0.0 0.45 ± 0.0 2.13 ± 1.5  0.83 ± 0.2 
iv ABCB5+ 0.25 ± 0.0 0.47 ± 0.0 2.45 ± 1.7 1.04 ± 0.4 
ip ABCB5+ 0.23 ± 0.0 0.46 ± 0.0 2.06 ± 1.4 1.40 ± 1.8 
CM 0.20 ± 0.0 0.33 ± 0.0* 0.54 ± 0.1* 0.52 ± 0.1 
CM+ 0.17 ± 0.0 0.35 ± 0.0 0.89 ± 0.4 0.58 ± 0.1 
CoCM+ 0.21 ± 0.0 0.37 ± 0.0** 1.43 ± 0.6 0.68 ± 0.1* 
Vehicle  0.24 ± 0.0 0.50 ± 0.0 1.37 ± 0.6 0.82 ± 0.1 
 
 
Urea   
(mg/dl) 
Cisplatin 35.36 ± 4.4 67.17 ± 4.1 258.70 ± 195.9 83.23 ± 30.5 
iv ABCB5+ 34.60 ± 4.4 71.75 ± 10.9 267.35 ± 162.0 120.93 ± 85.7 
ip ABCB5+ 36.03 ± 3.1 72.76 ± 9.8 258.67 ± 184.6 87.61 ± 32.9 
CM 34.30 ± 3.6 40.83 ± 5.3* 85.97 ± 33.4 56.43 ± 14.2 
CM+ 35.03 ± 4.9 52.63 ± 0.1 140.07 ± 63.7 63.40 ± 5.4 
CoCM+ 32.19 ± 4.6 60.63 ± 12.8 233.94 ± 81.0 74.54 ± 15.0 
Vehicle  33.50 ± 1.8 72.93 ± 11.9 161.67 ± 73.9 72.77 ± 22.4 
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Glucose 
(mg/dl) 
Cisplatin 149.06 ± 7.8 158.66 ± 18.2 160.33 ± 13.1 142.53 ± 6.9 
iv ABCB5+ 158.08 ± 18.1 164.08 ± 15.0 150.17 ± 18.5* 154.67 ± 12.1* 
ip ABCB5+ 173.18 ± 38.0 153.72 ± 6.9 156.00 ± 18.5  141.09 ± 6.47 
CM 159.67 ± 4.5 166.33 ± 4.7 167.00 ± 13.9  158.00 ± 4.58* 
CM+ 168.33 ± 9.0 167.33 ± 11.4 153.00 ± 4.3 147.67 ± 4.16 
CoCM+ 156.54 ± 6.9 163.27 ± 13.2 158.09 ± 30.0 149.91 ± 13.8 
Vehicle  159.33 ± 9.9 159.33 ± 15.6 147.67 ± 8.9 155.33 ± 5.7* 
 
 
Protein 
(mg/dl) 
Cisplatin 55.53 ± 1.8 60.26 ± 2.1 55.66 ± 2.9 56.26 ± 3.1 
iv ABCB5+ 55.50 ± 2.5 59.41 ± 1.9 55.75 ± 2.9 57.92 ± 2.3 
ip ABCB5+ 56.72 ± 2.4 60.81 ± 2.7 54.54 ± 2.4 56.91 ± 1.7 
CM 54.00 ± 3.0 56.67 ± 1.5* 56.00 ± 2.6 57.33 ± 0.6 
CM+ 56.67 ± 1.5 59.33 ± 2.1 57.00 ± 1.7 58.00 ± 0.0 
CoCM+ 54.72 ± 2.1 58.18 ± 3.4 53.91 ± 4.7 55.54 ± 1.9 
Vehicle  58.33 ± 2.1 59.00 ± 4.3 54.33 ± 2.1 55.33 ± 4.7 
 
 
Cholesterol 
(mg/dl) 
Cisplatin 96.00 ± 12.5 140.20 ± 21.5 113.20 ± 24.3 117.93 ± 15.7 
iv ABCB5+ 100.17 ± 10.5 142.42 ± 11.1 118.17 ± 13.9 129.58 ± 22.5 
ip ABCB5+ 94.18 ± 14.0 148.36 ± 21.3* 105.82 ± 17.3 114.00 ± 17.2 
CM 107.67 ± 14.9 138.67 ± 17.6 90.33 ± 14.6 104.33 ± 10.5 
CM+ 108.33 ± 15.3 144.67 ± 20.5 106.00 ± 24.9 109.67 ± 9.1 
CoCM+ 107.36 ± 16.2 150.27 ± 11.8 117.64 ± 20.5 122.00 ± 14.2 
Vehicle  88.00 ± 8.5 135.67 ± 18.44 117.67 ± 21.4 122.00 ± 23.4 
 
 
Triglycerides 
(mg/dl) 
Cisplatin 94.40 ± 26.5 73.33 ± 27.0 130.00 ± 37.8 127.33 ± 38.8 
iv ABCB5+ 115.58 ± 37.3 66.92 ± 11.1 124.67 ± 33.5 127.83 ± 33.1 
ip ABCB5+ 118.00 ± 39.7 68.18 ± 10.0 127.18 ± 50.3 148.73 ± 45.3 
CM 131.67 ± 16.7 64.67 ± 3.2 215.00 ± 41.6* 178.00 ± 56.4 
CM+ 122.33 ± 26.1 76.33 ± 29.9 182.33 ± 31.9 166.67 ± 37.9 
CoCM+ 95.64 ± 29.5 70.54 ± 21.4 115.00 ± 36.4 159.73 ± 37.1 
Vehicle  151.67 ± 57.9 61.67 ± 12.7 156.67 ± 55.7 84.33 ± 21.5 
 
 
AST 
(U/l) 
Cisplatin 52.8 ± 11.5 39.92 ± 6.7 61.93 ± 35.8 51.20 ± 20.8 
iv ABCB5+ 54.00 ± 12.7 37.83 ± 7.0 47.92 ± 16.2 49.17 ± 27.4 
ip ABCB5+ 64.45 ± 15.0 43.36 ± 7.7 74.45 ± 25.7 58.27 ± 18.0 
CM 38.00 ± 6.2 39.67 ± 6.0 38.00 ± 32.5 51.33 ± 19.6 
CM+ 45.33 ± 16.3 35.67 ± 3.8 67.00 ± 22.9 50.67 ± 33.0 
CoCM+ 54.27 ± 13.2 41.45 ± 7.7 71.09 ± 12.6 59.54 ± 12.6 
Vehicle  78.00 ± 6.9 52.33 ± 10.2 76.33 ± 15.9 68.33 ± 33.2 
 
 
ALT 
(U/l) 
Cisplatin 100.53 ± 5.3 104.46 ± 12.7 97.60 ±18.5 91.13 ± 14.2 
iv ABCB5+ 88.08 ± 14.9 96.75 ± 16.1 90.17 ± 20.0 98.75 ± 30.6 
ip ABCB5+ 97.73 ± 27.1 108.81 ± 14.9 98.64 ± 13.9 92.70 ± 13.5 
CM 86.00 ± 1.7 94.33 ± 19.3 87.00 ± 11.1 86.33 ± 2.3 
CM+ 86.67 ± 9.6 92.00 ± 10.5 81.33 ± 4.9 81.00 ± 7.2 
CoCM+ 87.09 ± 6.6 107.45 ± 23.4 97.09 ± 14.1 80.36 ± 10.2 
Vehicle  88.67 ± 9.9 150.33 ± 50.6 125.67 ± 37.2 101.33 ± 17.7 
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GGT 
(U/l) 
Cisplatin 3.00 ± 0.0 3.66 ± 0.9 3.26 ± 0.1 3.00 ± 0.0 
iv ABCB5+ 3.00 ± 0.0 3.00 ± 0.0 3.17 ± 1.3 3.00 ± 0.0 
ip ABCB5+ 3.00 ± 0.0 3.00 ± 0.0 3.54 ± 1.3 3.63 ± 1.3* 
CM 3.00 ± 0.0 3.00 ± 0.0 3.00 ± 0.0 3.00 ± 0.0 
CM+ 3.00 ± 0.0 3.00 ± 0.0 3.00 ± 0.0 3.00 ± 0.0 
CoCM+ 3.00 ± 0.0 3.00 ± 0.0 3.00 ± 0.0 3.00 ± 0.0 
Vehicle  3.00 ± 0.0 3.00 ± 0.0 2.67 ± 0.6 3.00 ± 0.0 
 
 
GLDH 
(U/l) 
Cisplatin 8.60 ± 1.3 9.13 ± 2.1 19.2 ± 4.5 4.91 ± 1.2 
iv ABCB5+ 7.50 ± 3.5 9.22± 1.9 19.94 ± 30.2 6.48 ± 2.7 
ip ABCB5+ 6.60 ± 1.4 9.74 ± 1.6 16.72 ± 16.5 6.51 ± 3.9 
CM 6.54 ± 0.5 8.99 ± 1.0 5.18 ± 0.9* 4.93 ± 1.1 
CM+ 6.56 ± 0.8 12.24 ± 6.3 7.31 ± 3.4 4.19 ± 0.3 
CoCM+ 6.89 ± 1.0 10.58 ± 4.1 12.50 ± 3.9 3.67 ± 0.4* 
Vehicle  6.22 ± 2.0 8.33 ± 1.6 11.99 ± 4.5 6.45 ± 0.7 
 
 
Na 
(mmol/l) 
Cisplatin 139.53 ± 4.5 140.13 ± 1.5 138.00 ± 4.2 139.36 ± 2.7 
iv ABCB5+ 142.75 ± 1.4 140.75 ± 1.2 139.33 ± 2.2 142.00 ± 3.1 
ip ABCB5+ 142.45 ± 0.9 141.82 ± 1.2** 141.64 ± 4.4* 141.45 ± 2.5 
CM 139.33 ± 0.6 143.00 ± 1.0* 144.33 ± 3.2* 143.67 ± 0.6* 
CM+ 138.00 ± 1.0 141.67 ± 1.1 142.67 ± 2.1* 142.33 ± 3.2 
CoCM+ 140.82 ± 1.5 138.82 ± 2.4* 141.36 ± 4.9 140.82 ± 3.6 
Vehicle  143.67 ± 2.9 140.33 ± 2.1 139.67 ± 1.5 140.00 ± 2.6 
 
 
Ca 
(mmol/l) 
Cisplatin 2.71 ± 0.0 2.73 ± 0.0 4.75 ± 7.6 2.84  ± 0.0 
iv ABCB5+ 2.71 ± 0.1 2.72 ± 0.0 2.89 ± 0.2 2.88 ± 0.1 
ip ABCB5+ 2.71 ± 0.1 2.75 ± 0.1 2.80 ± 0.1 2.80 ± 0.1 
CM 2.71 ± 0.1 2.67 ± 0.1 2.74 ± 0.1 2.85 ± 0.1 
CM+ 2.73 ± 0.0 2.69 ± 0.0 2.81 ± 0.1 2.88 ± 0.0 
CoCM+ 2.71 ± 0.0 2.70 ± 0.0 2.74 ± 0.1 2.88 ± 0.1 
Vehicle  2.76 ± 0.0 2.73 ± 0.0 2.84 ± 0.1 2.69 ± 0.1 
 
 
K 
(mmol/l) 
Cisplatin 4.95 ± 0.3 4.19 ± 0.3 4.77 ± 0.5 5.55 ± 0.6 
iv ABCB5+ 5.20 ± 0.3 4.14 ± 0.2 5.34 ± 0.4* 5.90 ± 0.6 
ip ABCB5+ 5.37 ± 0.4 4.28 ± 0.2 5.08 ± 0.4 5.43 ± 0.5 
CM 5.11 ± 0.3 4.38 ± 0.5 5.13 ± 0.3 5.59 ± 0.3 
CM+ 5.69 ± 0.2 4.19 ± 0.1 5.63 ± 0.1* 6.45 ± 0.5 
CoCM+ 5.26 ± 0.2 4.15 ± 0.3 4.99 ± 0.6 5.84 ± 0.6 
Vehicle  5.14 ± 0.3 4.26 ± 0.2 4.94 ± 0.2 5.77 ± 0.7 
 
 
PO4 
 (mmol/l) 
Cisplatin 2.75 ± 0.1 2.47 ± 0.2 2.20 ± 0.9 1.41 ± 0.5 
iv ABCB5+ 2.51 ± 0.3 2.46 ± 0.2 2.07 ± 1.0 1.32 ± 0.3 
ip ABCB5+ 2.57 ± 0.4 2.51 ± 0.2 1.89 ± 0.6 1.34 ± 0.6 
CM 2.64 ± 0.2 2.70 ± 0.1 1.47 ± 0.4 1.99 ± 0.4 
CM+ 2.71 ± 0.1 2.73 ± 0.1 1.46 ± 0.2 1.70 ± 0.5 
CoCM+ 2.44 ± 0.1 2.47 ± 0.2 1.65 ± 0.5 1.23 ± 0.3 
Vehicle  2.33 ± 0.3 2.40 ± 0.3 1.74 ± 0.2 1.61 ± 0.6 
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Table 7 Changes in plasma biochemistry in the experimental groups (cisplatin n=15; iv ABCB5+ n=12; ip 
ABCB5+ n=11; CM n=3; CM+ n=3; CoCM+ n=11; Vehicle n=3). Data are shown as means ± SD. Values 
significantly different from cisplatin group are indicated as *p< 0.05 and **p< 0.005 
 
 
 
On day 7, plasma creatinine decreased by 3.9 (p<0.05), 2.4 and 1.5 times in animals treated 
with CM, CM+ and co-CM+ respectively when compared to the cisplatin treated group, and 
remain low on day 14. Plasma urea decreased on day 7 by 3 and 1.8 times in animals treated 
with CM and CM+ respectively and remain low on day 14 when compared to the cisplatin 
treated group. No particular changes were found in animals who received ABCB5+ cells 
compared to cisplatin treated animals (Figure 18).  
 
 
Figure 18 Effect of different treatments on a cisplatin-induced nephrotoxicity model in plasma creatinine and urea 
concentration. Statistically significant differences (treatment vs cisplatin) are indicated as *p< 0.05 and **p< 
0.005.  
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Among the hepatic enzymes, GLDH levels decreased on day 7 by 3.7 (p<0.05) and 2.6 times 
in animals treated with CM and CM+ respectively. On day 14, GLDH levels were found 
significantly decreased by 1.3 times in co-CM+ treated animals compared to the cisplatin 
model. No changes were found in animals who received ABCB5+ cells compared to cisplatin 
treated animals (Figure 19).  
 
 
Figure 19 Effect of different treatments on a cisplatin-induced nephrotoxicity model in plasma GLDH level. 
Statistically significant differences (treatment vs cisplatin) are indicated as *p< 0.05 and **p< 0.005. 
 
 
 
Plasma triglycerides significantly increase on day 7 (p<0.05) in animals treated with CM 
compared with the cisplatin treated group. 
 
No other significant changes of other plasma parameters were observed.  
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Animals who received the vehicle did not show any particular differences in plasma parameters 
compared to the cisplatin-treated animals.  
 
 
 
4.2.2. ABCB5+ cells/conditioned media effect on urine parameters 
 
Urine was collected as described in section 3.3. Urine biochemistry results are summarized in 
Table 8.  
 
Parameter Group Baseline Day 2 Day 7 Day 14 
 
 
Creatinine 
(mg/16h) 
Cisplatin 7.24 ± 1.4 8.19 ± 2.3 7.10 ± 2.2 7.94 ± 1.8 
iv ABCB5+ 7.51 ± 1.6 7.92 ± 1.9 7.01 ± 2.0 7.04 ± 1.5 
ip ABCB5+ 7.51 ± 1.2 6.86 ± 1.5 6.99 ± 1.3 7.15 ± 1.4 
CM 5.39 ± 0.6 9.94 ± 2.5 8.35 ± 1.4 8.09 ± 1.4 
CM+ 4.87 ± 0.5 6.22 ± 0.5* 7.11 ± 0.6 7.24 ± 1.1 
CoCM+ 5.51 ± 0.7 5.53 ± 1.3** 6.94 ± 1.5 5.31 ± 1.8** 
Vehicle 8.0 ± 1.9 8.69 ± 1.0 8.23 ± 1.1 8.88 ± 2.8 
 
 
Urea  
(mg/16h) 
Cisplatin 431.60 ± 82.5 496.33 ± 129.7 616.61 ± 220.5 588.45 ± 82.1 
iv ABCB5+ 460.11 ± 106.6 430.26 ± 109.26 537.44 ± 159.9 560.55 ± 89.4 
ip ABCB5+ 446.76 ± 155.2 438.63 ± 45.52 555.73 ± 93.1 546.64 ± 114.2 
CM 379.38 ± 39.2 655.66 ± 205.9 993.00 ± 302.8 540.42 ± 66.0 
CM+ 409.05 ± 21.7 417.28 ±117.1 638.72 ± 125.7 548.10 ± 83.3 
CoCM+ 421.85 ± 81.0 350.14 ± 94.4** 721.38 ± 192.7 485.28 ± 167.3 
Vehicle 424.89 ± 163.2 447.56 ± 88.9 584.9 ± 180.6 512.14 ± 72.4 
 
 
Glucose 
(mg/16h) 
Cisplatin 3.33 ± 1.1 10.81 ± 6.9 63.37 ± 42.3 100.76 ± 87.5 
iv ABCB5+ 4.08 ± 1.0 8.01 ± 3.8 81.39 ± 47.3 89.80 ± 73.6 
ip ABCB5+ 4.05 ± 0.8 6.18 ± 4.5 61.49 ± 25.7 98.12 ± 117.4 
CM 2.17 ± 1.8 1.99 ± 2.1 4.75 ± 4.8* 0.87 ± 0.1** 
CM+ 2.44 ± 1.9 5.35 ± 6.0 39.88 ± 31.4 78.24 ± 118.4 
CoCM+ 3.56 ± 0.8 4.29 ± 3.7* 56.56 ± 29.6 50.95 ± 56.8 
Vehicle 3.67 ± 0.5 10.72 ± 2.7 39.91 ± 28.9 80.57 ± 65.5 
 
 
Protein 
(mg/16h) 
Cisplatin 8.12 ± 3.2 12.9 ± 1.1 8.85 ± 3.1 12.17 ± 4.6 
iv ABCB5+ 7.80 ± 3.2 12.11 ± 4.5 9.32 ± 3.8 10.41 ± 4.1 
ip ABCB5+ 8.96 ± 3.3 11.34 ± 3.6 9.18 ± 2.6 14.18 ± 5.0 
CM 4.41 ± 1.5 9.42 ± 2.4 10.22 ± 6.5 10.03 ± 1.5 
CM+ 5.16 ± 1.1 10.95 ± 3.4 9.94 ± 0.8 11.67 ± 2.7 
CoCM+ 6.04 ± 2.8 12.50 ± 19.6* 8.41 ± 2.0 8.56 ± 4.9 
Vehicle  9.73 ± 4.7 16.13 ± 7.2 9.43 ± 1.8 15.03 ± 1.2 
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Albumin 
(mg/16h) 
Cisplatin 0.21 ± 0.1 2.71 ± 1.3 4.92 ± 2.3 4.24 ± 2.8 
iv ABCB5+ 0.25 ± 0.1 2.67 ± 0.7 4.68 ± 1.8 4.67 ± 3.1 
ip ABCB5+ 0.21± 0.0 2.63 ± 0.8 5.05 ± 1.7 5.03 ± 3.0 
CM 0.21 ± 0.0 1.44 ± 0.1 3.43 ± 3.2 1.08 ± 0.7 
CM+ 0.20 ± 0.1 2.26 ± 0.9 3.13 ± 0.4 2.01 ± 1.4 
CoCM+ 0.23 ± 0.1 1.79 ± 0.5* 4.82 ± 1.4 2.28 ± 2.3 
Vehicle  0.30 ± 0.1 2.59 ± 0.7 3.60 ± 1.0 4.09 ± 2.8 
 
 
Na 
(mmol/16h) 
Cisplatin 2.08 ± 0.4 1.53 ± 1.0 1.71 ± 0.9 2.20 ± 0.7 
iv ABCB5+ 1.94 ± 0.4 1.13 ± 0.4 1.57 ± 0.7 2.48 ± 0.7 
ip ABCB5+ 1.85 ± 0.3 1.11 ± 0.3 1.46 ± 0.6 2.24 ± 0.3 
CM 1.92 ± 0.0 1.54 ± 0.5 1.25 ± 0.8 2.73 ± 0.7 
CM+ 2.03 ± 0.4 1.20 ± 0.1 1.19 ± 0.8 2.83 ± 0.5 
CoCM+ 2.16 ± 0.6 1.07 ± 0.3 1.08 ± 0.5* 2.04 ± 0.8 
Vehicle  1.81 ± 0.8 1.17 ± 0.1 1.01 ± 0.1 1.99 ± 0.8 
 
 
Ca 
(mmol/16h) 
Cisplatin 0.02 ± 0.0 0.03 ± 0.0 0.08 ± 0.0 0.18 ± 0.0 
iv ABCB5+ 0.02 ± 0.0 0.04 ± 0.0 0.11 ± 0.0 0.19 ± 0.1 
ip ABCB5+ 0.02 ± 0.0 0.04 ± 0.0 0.10 ± 0.0 0.19 ± 0.1 
CM 0.02 ± 0.0 0.10 ± 0.1 0.09 ± 0.0 0.19 ± 0.1 
CM+ 0.03 ± 0.0 0.04 ± 0.0 0.11 ± 0.1 0.18 ± 0.1 
CoCM+ 0.03 ± 0.0 0.04 ± 0.0 0.08 ± 0.0 0.22 ± 0.1 
Vehicle  0.01 ± 0.0 0.03 ± 0.0 0.10 ± 0.0 0.18 ± 0.1 
 
 
K 
(mmol/16h) 
Cisplatin 3.80 ± 0.5 2.52 ± 0.6 2.62 ± 1.4 3.88 ± 1.4 
iv ABCB5+ 3.76± 0.9 2.27 ± 0.5 2.42 ± 0.8 3.76 ± 0.8 
ip ABCB5+ 3.84 ± 0.6 1.90 ± 0.6* 2.51 ±0.8 4.26 ± 0.8 
CM 4.08 ± 0.3 2.91 ± 0.7 3.54 ± 0.6 6.15 ± 0.4* 
CM+ 4.06 ± 0.2 2.14 ± 0.2 2.89 ± 1.3 5.50± 0.8 
CoCM+ 4.07 ± 0.9 1.88 ± 0.6* 2.16 ± 0.9 3.49± 1.1 
Vehicle  3.42 ± 1.0 2.74 ± 0.5 2.72 ± 0.6 4.63 ± 1.4 
 
 
PO4 
(mmol/16h) 
Cisplatin 0.13 ± 0.0 0.59 ± 0.3 0.19 ± 0.1 0.05 ± 0.0 
iv ABCB5+ 0.11 ± 0.1 0.57 ± 0.1 0.16 ± 0.1 0.05 ± 0.0 
ip ABCB5+ 0.14 ± 0.1 0.55 ± 0.1 0.14 ± 0.1 0.04 ± 0.0 
CM 0.10 ± 0.0 0.67 ± 0.1 0.15 ± 0.1 0.05 ± 0.0 
CM+ 0.17 ± 0.1 0.60 ± 0.1 0.09 ± 0.1 0.03 ± 0.0* 
CoCM+ 0.07 ± 0.0 0.46 ± 0.1 0.21 ± 0.1 0.03 ± 0.0 
Vehicle  0.14 ± 0.1 0.57 ± 0.1 0.20 ± 0.1 0.05 ± 0.0 
Table 8 Changes in urine biochemistry in the experimental groups (cisplatin n=15; iv ABCB5+ n=12; ip ABCB5+ 
n=11; CM n=3; CM+ n=3; CoCM+ n=11; Vehicle n=3). Values were normalized to the volume of urine produced 
in 16 hours.  Data are shown as means ± SD. Values significantly different from cisplatin group are indicated as 
*p< 0.05 and **p< 0.005.  
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Urine albumin levels decreased from day 7 onward in animals treated with all kind of 
conditioned media. On day 14, albuminuria decreased by 4.2, 2.1 and 1.8 times in animals 
treated with CM, CM+ and co-CM+ respectively when compared to the cisplatin treated group. 
No changes were found in animals who received ABCB5+ cells compared to the cisplatin 
treated animals (Figure 20).  
 
 
 
Figure 20 Albuminuria found by different treatments on a cisplatin-induced nephrotoxicity mode. Values were 
normalized to the volume of urine produced in 16 hours. Statistically significant differences (treatment vs cisplatin) 
are indicated as *p< 0.05 and **p< 0.005. 
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Only in CM treated animals, glycosuria significantly decreased on day 7 (p<0.05) and 14 
(p<0.005) (Figure 21).   
 
 
Figure 21 Glycosuria found by different treatments on a cisplatin-induced nephrotoxicity model. Values were 
normalized to the volume of urine produced in 16 hours. Statistically significant differences (treatment vs cisplatin) 
are indicated as *p< 0.05 and **p< 0.005. 
 
 
 
No other significant changes of other urine parameters were observed. 
 
Animals who received the vehicle did not show any particular differences in urine parameters 
compared to the cisplatin-treated animals.  
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4.2.3. ABCB5+ cells/conditioned media effect on renal function 
 
Transcutaneous assessment of renal function was performed as described in section 3.4. Values 
of ABZWCY-HPβCD half-life are summarized in Table 9. 
 
Parameter Group Baseline Day 2 Day 7 Day 14 
 
 
 
Half-life  
(min) 
Cisplatin 38.67 ± 7.8 69.64 ± 10.3 68.01 ± 19.1 82.73 ± 38.3  
iv ABCB5+ 32.44 ± 6.7 69.62 ± 25.9 129.19 ± 63.2* 100.64 ± 22.9 
ip ABCB5+ 32.12 ± 6.6 70.11 ± 18.1 109.50 ± 40.7* 101.48 ± 26.8 
CM 31.10 ± 6.2 29.40 ● 61.27 ± 4.1 68.87 ± 19.6 
CM+ 31.33 ± 6.9 60.10 ● 38.55 ± 0.2 72.37 ± 22.7 
CoCM+ 32.04 ± 4.5 59.38 ± 19.24 115.81 ± 33.0* 69.15 ± 20.5 
Vehicle  26.00 ± 14.9 69.13 ± 30.12 100.80 ± 24.4 84.00 ± 3.8 
Table 9 Changes in ABZWCY-HPβCD half-life. Experimental groups: cisplatin n=15; iv ABCB5+ n=12; ip 
ABCB5+ n=11; CM n=3; CM+ n=3; CoCM+ n=11; vehicle n=3. Data are shown as means ± SD. Values 
significantly different from control are indicated as *p< 0.05 and **p< 0.005. ● data of only one animal 
 
 
On day 7, animals treated with ABCB5+ cells and coCM+ showed a higher ABZWCY-HPβCD 
half-life when compared to the cisplatin treated animals (p<0.05), while the CM+ group had a 
1.8-times smaller ABZWCY-HPβCD half-life. One week later, animals treated with the 3 
different conditioned media had a similar ABZWCY-HPβCD excretion time, which was lower 
than in the control, while animals treated with ABCB5+ cells maintained a high ABZWCY-
HPβCD half-life (Figure 22).  
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Figure 22 Transcutaneous assessment of renal function (ABZWCY-HPβCD half-life). Effect of different 
treatments on a cisplatin-induced nephrotoxicity model. Statistically significant differences (treatment vs cisplatin) 
are indicated as *p< 0.05 and **p< 0.005. 
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4.2.4. ABCB5+ cells/conditioned media effect on body weight, diuresis, food and 
water intake 
 
 
Before and after being in metabolic cages for 16 hours, changes in diuresis, BW, food and water 
intake were recorded. The values are summarized in Table 10. 
 
 
Parameter Group Baseline Day 2 Day 7 Day 14 
 
 
Diuresis 
(ml/16h) 
Cisplatin 11.68 ± 2.0 16.18 ± 10.8 36.03 ± 10.0 37.19 ± 9.9 
iv ABCB5+ 13.55 ± 3.5 16.38 ± 13.5 40.50 ± 15.3 43.10 ± 7.3 
ip ABCB5+ 10.85 ± 1.7 16.81 ± 12.8 35.85 ± 3.8 38.18 ± 4.6 
CM 10.46 ± 2.2 30.30 ± 14.4 43.20 ± 7.6 34.70 ± 7.6 
CM+ 10.37 ± 1.7 16.00 ± 8.5 31.63 ± 3.9 30.03 ± 2.4 
CoCM+ 11.41 ± 3.4 21.23 ± 20.8 43.91 ± 17.9 32.38 ± 9.7 
Vehicle  14.13 ± 3.6 12.63 ± 3.9 39.80 ± 6.6 36.67 ± 7.4 
 
 
Water 
intake 
  (ml/16h) 
Cisplatin 26.38 ± 2.9 23.38 ± 16.8 56.35 ± 18.7 55.75 ± 12.5 
iv ABCB5+ 29.16 ± 4.7 21.50 ± 15.3 60.27 ± 13.4 61.09 ± 9.3 
ip ABCB5+ 25.50 ± 4.2 22.44 ± 13.6 51.69 ± 6.3 60.06 ± 6.8 
CM 28.67 ± 5.5 38.33 ± 15.3 78.67 ± 9.3* 58.67 ± 10.7 
CM+ 25.33 ± 4.7 19.67 ± 9.9 53.00 ± 11.3 47.33 ± 4.6 
CoCM+ 24.97 ± 5.6 27.52 ± 24.2 57.76 ± 25.8 59.28 ± 11.1 
Vehicle  25.00 ± 7.9 18.80 ± 4.13 64.47 ± 5.7 60.90 ± 11.9 
 
 
Body 
weight  
(g) 
Cisplatin 366.53 ± 33.5 395.47 ± 37.1 376.80 ± 49.9 386.27 ± 53.3 
iv ABCB5+ 371.41 ± 32.7 375.25 ± 53.7 340.25 ± 59.4 361.50 ± 63.7  
ip ABCB5+ 339.00 ± 39.7 358.91 ± 47.2 328.73 ± 54.9* 355.45 ± 57.9 
CM 295.67 ± 3.5 326.00 ± 14.0* 338.00 ± 29.5 382.67 ± 24.7 
CM+ 278.00 ± 8.1 294.67 ± 16.6** 291.67 ± 26.1* 337.67 ± 17.5 
CoCM+ 292.18 ± 16.4 325.27 ± 16.8** 288.64 ± 30.2** 341.27 ± 28.3* 
Vehicle  377.33 ± 33.0 378.67 ± 48.7 360.33 ± 49.9 384.33 ± 58.1 
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Food intake 
  (g/16h) 
Cisplatin 19.54 ± 3.1 8.93 ± 5.8 15.87 ± 5.3 21.39 ± 3.0 
iv ABCB5+ 21.69 ± 4.6 9.55 ± 3.5 15.47 ± 4.9 21.69 ± 3.2 
ip ABCB5+ 20.04 ± 3.7 8.77 ± 1.5 15.68 ± 3.9 22.14 ± 3.0 
CM 20.00 ± 8.2 11.33 ± 4.2 23.33 ± 0.6* 26.33 ± 3.0* 
CM+ 22.00 ± 1.0 10.00 ± 1.0 21.00 ± 2.6 24.33 ± 4.0 
CoCM+ 19.74 ± 3.5 8.47 ± 1.8 14.24 ± 6.4 23.99 ± 3.2 
Vehicle  22.80 ± 3.4 9.70 ± 0.6 17.17 ± 3.0 22.00 ± 2.7 
Table 10 Changes in body weight, diuresis, food and water intake before and after metabolic cage allocation. 
Experimental groups: cisplatin n=15; iv ABCB5+ n=12; ip ABCB5+ n=11; CM n=3; CM+ n=3; CoCM+ n=11; 
vehicle n=3. Data are shown as means ± SD. Values significantly different from control are indicated as *p< 0.05 
and **p< 0.005. 
 
 
Loss of weight gain, in a range of 20-30 g, was recorded between day 2 and 7 in animals who 
received ABCB5+ cells and coCM+. Animals who received CM and CM+ gained weight or 
maintained a quite stable weight (CM p<0.05). Accordingly, in these groups the food intake, 
which decreased on day 2, was higher than in the other animal groups (CM p<0.05).  
 
 
 
 
 
 
4.2.5. ABCB5+ cells/conditioned media effect on renal morphology 
 
 
Whole kidney scans displayed in Figure 23 show changes in the renal cytoarchitecture of 
animals treated with ABCB5+ cells and conditioned media. Animals that received ABCB5+ 
cells, both ip and iv, did not show any visible differences from the cisplatin treated animals. 
The cortical and juxtamedullary region was the most affected area with dilated proximal tubuli 
in the cortical region and protein cast accumulations mostly in the papillary region. Animals 
treated with conditioned media showed less severe damage in terms of affected area and protein 
cast accumulations. CM treated animals resulted to be affected mainly in the juxtamedullary 
region. 
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Figure 23 Effect of ABCB5+ cells and conditioned media on renal morphology. Whole kidney scan showing 
changes in the cytoarchitecture. A: control; B: cisplatin; C: ipABCB5+; D: ivABCB5+; E: CM; F: CM+; G: 
coCM+. H&E staining. Scale bars: 1mm. Images acquired with Axio Scan.Z1 microscope (ZEISS). 
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4.3. Gene expression analysis 
 
 
Gene expression analysis of renal tissue obtained from sacrificed animals was performed. The 
analysis was first performed with both microarray and RNAseq, showing reliable results with 
both approaches. However, due to its innovative and more sensitive methodology, and for the 
possibility to additionally performed miRNAs profiling, RNAseq was chosen over microarray 
for subsequent analyses.  
 
 
 
4.3.1. Cisplatin effect on gene expression: microarray vs RNAseq analysis 
 
Distribution and batch normalization of the data were first performed. PCA and cluster analysis 
of 3 healthy and 3 cisplatin-treated animals showed 2 distinct clusters with both microarray and 
RNAseq. (Figure 24).  
 
Figure 24 Heatmap showing cluster analysis of treated (cisplatin, n=3) and untreated (control, n=3) animals with 
both microarray (on the left) and RNAseq (on the right) 
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From the 21569 genes screened in the microarray, 6651 were significant differentially 
expressed (3656 upregulated and 2995 downregulated genes) in the cisplatin-treated animals 
compared to the controls (adj. p<0.05). Similarly, from the 17322 genes screened, 6333 
differentially expressed genes (3310 upregulated and 3023 downregulated genes) were detected 
with RNAseq. The Venn diagram in Figure 25 shows that 4087 genes were found with both 
microarray and RNAseq technology. Linear regression fitted for log2 fold change (log2FC) 
cisplatin vs control of the common genes determined via microarray and RNAseq was 
performed and showed a correlation with R-square= 0.82 and p-value< 0.000 (Figure 25). 
 
 
 
Figure 25 Venn diagram of differentially expressed genes with RNAseq and microarray (left). Linear regression 
fitted for log2FC of selected common genes determined via microarray and RNAseq technology (right). R: R-
square.  
 
 
 
Successively, GSEA using the KEGG database was performed. Conventionally, considering a 
list of differentially expressed ranked genes organized in gene set, a positive (or negative) NES 
indicate the position of a pathway at the top (or at the bottom) of the gene list, meaning that the 
genes which belong to that pathway are highly (or low) expressed. From 123 selected 
significant pathways, 73 pathways were commonly detected with both microarray and RNAseq 
and showed similar NES values, indicating reliability of the results obtained by using the two 
techniques (Table 11).  
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NES NES 
 Microarray RNAseq
Carbon metabolism 1.0 Global and overview maps -2.6 -2.5
Oxocarboxylic acid metabolism 1.0 Global and overview maps -1.7 -1.7
Fatty acid metabolism 1.0 Global and overview maps -2.0 -2.0
Biosynthesis of amino acids 1.0 Global and overview maps -2.1 -2.0
Glycolysis / Gluconeogenesis 1.1 Carbohydrate metabolismabolism -2.1 -2.0
Citrate cycle (TCA cycle) 1.1 Carbohydrate metabolismabolism -2.2 -2.3
Pentose and glucuronate interconversions 1.1 Carbohydrate metabolismabolism -1.9 -2.0
Ascorbate and aldarate metabolism 1.1 Carbohydrate metabolismabolism -2.1 -2.2
Pyruvate metabolism 1.1 Carbohydrate metabolismabolism -2.5 -2.2
Glyoxylate and dicarboxylate metabolism 1.1 Carbohydrate metabolismabolism -2.5 -2.2
Propanoate metabolism 1.1 Carbohydrate metabolismabolism -2.5 -2.1
Butanoate metabolism 1.1 Carbohydrate metabolismabolism -2.4 -1.9
Metabolism of xenobiotics by cyt P450 1.11 Xenobiotics metabolismabolism -2.0 -2.1
Drug metabolism - cytochrome P450 1.11 Xenobiotics metabolismabolism -2.2 -2.2
Drug metabolism - other enzymes 1.11 Xenobiotics metabolismabolism -1.5 -2.1
Oxidative phosphorylation 1.2 Energy metabolismabolism -2.4 -2.5
Fatty acid elongation 1.3 Lipid metabolismabolism -1.9 -1.9
Fatty acid degradation 1.3 Lipid metabolismabolism -2.4 -2.2
Steroid hormone biosynthesis 1.3 Lipid metabolismabolism -1.9 -1.9
Glycerolipid metabolism 1.3 Lipid metabolismabolism -2.1 -1.8
Biosynthesis of unsaturated fatty acids 1.3 Lipid metabolismabolism -1.7 -1.8
Glycine, serine and threonine met 1.5 Amino acid metabolismabolism -2.8 -2.2
Cysteine and methionine metabolism 1.5 Amino acid metabolismabolism -2.2 -2.0
Valine, leucine and isoleucine degradation 1.5 Amino acid metabolismabolism -2.8 -2.3
Lysine degradation 1.5 Amino acid metabolismabolism -1.5 -2.0
Arginine and proline metabolism 1.5 Amino acid metabolismabolism -2.4 -1.8
Histidine metabolism 1.5 Amino acid metabolismabolism -2.2 -1.9
Tyrosine metabolism 1.5 Amino acid metabolismabolism -1.9 -1.9
Tryptophan metabolism 1.5 Amino acid metabolismabolism -2.4 -2.2
beta-Alanine metabolism 1.6 Metabolism of other amino acids -2.5 -2.2
Selenocompound metabolism 1.6 Metabolism of other amino acids -2.1 -1.8
Glutathione metabolism 1.6 Metabolism of other amino acids -2.2 -2.0
Glycosaminoglycan biosynthesis 1.7 Glycan biosynthesis and metabolism 1.7 1.8
Nicotinate and nicotinamide metabolism 1.8 Metabolism of cofactors and vitamins -1.9 -1.6
Pantothenate and CoA biosynthesis 1.8 Metabolism of cofactors and vitamins -1.9 -1.8
Folate biosynthesis 1.8 Metabolism of cofactors and vitamins -1.8 -1.9
Retinol metabolism 1.8 Metabolism of cofactors and vitamins -1.7 -1.9
Porphyrin and chlorophyll metabolism 1.8 Metabolism of cofactors and vitamins -1.8 -1.9
Terpenoid backbone biosynthesis 1.9 Metabolism of terpenoids and polyketides -1.7 -1.6
Spliceosome 2.1 Transcription 1.7 1.7
Aminoacyl-tRNA biosynthesis 2.2 Translation -1.8 -1.7
MAPK signaling pathway 3.2 Signal transduction 2.0 1.4
Rap1 signaling pathway 3.2 Signal transduction 2.0 1.3
NF-kappa B signaling pathway 3.2 Signal transduction 2.5 1.9
PI3K-Akt signaling pathway 3.2 Signal transduction 2.2 1.4
Notch signaling pathway 3.2 Signal transduction 1.9 1.8
Hippo signaling pathway 3.2 Signal transduction 2.1 1.4
Jak-STAT signaling pathway 3.2 Signal transduction 2.2 1.6
TNF signaling pathway 3.2 Signal transduction 2.3 1.9
Cytokine-cytokine receptor interaction 3.3 Signaling molecules and interaction 2.2 2.1
ECM-receptor interaction 3.3 Signaling molecules and interaction 2.3 1.7
Cell adhesion molecules (CAMs) 3.3 Signaling molecules and interaction 2.3 2.2
Phagosome 4.1 Transport and catabolism 2.3 1.8
Peroxisome 4.1 Transport and catabolism -2.7 -2.3
Regulation of actin cytoskeleton 4.2 Cell motility 2.3 1.4
Cell cycle 4.3 Cell growth and death 2.3 2.0
p53 signaling pathway 4.3 Cell growth and death 2.1 1.9
Apoptosis 4.3 Cell growth and death 2.3 1.6
Focal adhesion 4.4 Cellular community 2.5 1.6
KEGG pathway Sub category
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Chemokine signaling pathway 5.1 Immune system 2.3 1.7
Complement and coagulation cascades 5.1 Immune system 1.8 1.6
Platelet activation 5.1 Immune system 2.0 1.5
Antigen processing and presentation 5.1 Immune system 2.2 1.9
Toll-like receptor signaling pathway 5.1 Immune system 2.2 1.8
NOD-like receptor signaling pathway 5.1 Immune system 1.9 1.5
Hematopoietic cell lineage 5.1 Immune system 2.1 2.0
Natural killer cell mediated cytotoxicity 5.1 Immune system 2.5 1.9
T cell receptor signaling pathway 5.1 Immune system 2.3 1.5
B cell receptor signaling pathway 5.1 Immune system 2.4 1.7
Fc gamma R-mediated phagocytosis 5.1 Immune system 2.4 1.6
Leukocyte transendothelial migration 5.1 Immune system 2.3 1.7
Intestinal immune network for IgA prod. 5.1 Immune system 1.9 1.8
Renin-angiotensin system 5.2 Endocrine system -1.6 -1.7  
Table 11 GSEA analysis using KEGG database sorted by subcategory: significant (adjusted p-value< 0.05) 
differentially expressed pathways (cisplatin vs control). For each pathway the normalized enrichment score (NES) 
obtained with microarray and RNAseq are given. Downregulated pathways are displayed in green, upregulated 
pathways in red. KEGG main categories: 1 metabolism; 2 genetic information processing; 3 environmental 
information processing; 4 cellular processes; 5 organismal system. 
 
 
An overview of what was discussed so far is shown in Table 12.  
 
Microarray RNAseq
Significant differentially expressed 6651 6333
Significant upregulated 3656 3310
Significant downregulated 2995 3023
Detected 298 305
Significant 201 139
Selected 111 85
Cisplatin vs control
G
e
n
e
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Table 12 Overview of differentially expressed genes and pathways in cisplatin vs control found with microarray 
and RNAseq: significance was attributed for an adjusted p-value< 0.05 
 
 
Based on the reliable results discussed so far and due to the innovative and more sensitive 
method used in the RNAseq technique, we chose RNAseq over microarray for the following 
analyses. 
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4.3.2. Cisplatin effect on gene expression: RNAseq analysis 
 
 
The GSEA analysis showed 49 significant differentially expressed pathways. As shown in 
Table 13, cisplatin led to upregulation of apoptosis and p53 signaling pathways. The renal tissue 
metabolism is downregulated and so the translational activity and protein processing.  
Differentially expressed KEGG pathways (adj. P-value < 0.05) RNAseq: cisplatin vs control
NES
RNAseq
Metabolic pathways 1. Metabolism 1.0 Global and overview maps -2.31
Carbon metabolism 1. Metabolism 1.0 Global and overview maps -2.46
Fatty acid metabolism 1. Metabolism 1.0 Global and overview maps -1.97
Biosynthesis of amino acids 1. Metabolism 1.0 Global and overview maps -1.96
Oxocarboxylic acid metabolism 1. Metabolism 1.0 Global and overview maps -1.69
Metabolism of xenobiotics by cytochrome P450 1. Metabolism 1.11 Xenobiotics biodegradation and metabolism -2.1
Drug metabolism (982) 1. Metabolism 1.11 Xenobiotics biodegradation and metabolism -2.22
Drug metabolism (983) 1. Metabolism 1.11 Xenobiotics biodegradation and metabolism -2.13
Aminoacyl-tRNA biosynthesis 2. Genetic Information Processing 2.2 Translation -1.7
Protein processing in endoplasmic reticulum 2. Genetic Information Processing 2.3 Folding  sorting and degradation -1.79
Peroxisome 4. Cellular Processes 4.1 Transport and catabolism -2.3
p53 signaling pathway 4. Cellular Processes 4.3 Cell growth and death 1.87
Apoptosis 4. Cellular Processes 4.3 Cell growth and death 1.62
Renin-angiotensin system 5. Organismal Systems 5.2 Endocrine system -1.67
Sub categoryKEGG pathway Main category
 
Table 13 GSEA analysis using KEGG database sorted by subcategory: significant (adjusted p-value< 0.05) 
differentially expressed pathways (cisplatin vs control). For each pathway the normalized enrichment score (NES) 
is given. Downregulated pathways are displayed in green (light green: -1.5 >NES> 0; green: -2 >NES>-1.5; dark 
green: NES >-2), upregulated pathways in red (light red: 1.5 >NES> 0; red: 2 >NES> 1.5; dark red: NES >2). 
 
 
 
In contrast, upregulation of DNA replication, cell cycle, ribosome and spliceosome assembly, 
and of several pathways involved in extracellular matrix (ECM) remodeling was found (Table 
14). 
Differentially expressed KEGG pathways (adj. P-value < 0.05) RNAseq: cisplatin vs control
NES
RNAseq
DNA replication 2. Genetic Information Processing 2.4 Replication and repair 1.68
Ribosome 2. Genetic Information Processing 2.2 Translation 1.63
Spliceosome 2. Genetic Information Processing 2.1 Transcription 1.7
Phagosome 4. Cellular Processes 4.1 Transport and catabolism 1.78
Cell cycle 4. Cellular Processes 4.3 Cell growth and death 2.03
Glycosaminoglycan biosynthesis 1. Metabolism 1.7 Glycan biosynthesis and metabolism 1.79
Cell adhesion molecules (CAMs) 3. Environmental Information Processing 3.3 Signaling molecules and interaction 2.24
Cytokine-cytokine receptor interaction 3. Environmental Information Processing 3.3 Signaling molecules and interaction 2.06
ECM-receptor interaction 3. Environmental Information Processing 3.3 Signaling molecules and interaction 1.73
Neuroactive ligand-receptor interaction 3. Environmental Information Processing 3.3 Signaling molecules and interaction 1.28
Regulation of actin cytoskeleton 4. Cellular Processes 4.2 Cell motility 1.35
Focal adhesion 4. Cellular Processes 4.4 Cellular community 1.55
KEGG pathway Main category Sub category
 
Table 14 GSEA analysis using KEGG database sorted by subcategory: significant (adjusted p-value< 0.05) 
differentially expressed pathways (cisplatin vs control). For each pathway the normalized enrichment score (NES) 
is given. Upregulated pathways are displayed in red (light red: 1.5 >NES> 0; red: 2 >NES> 1.5; dark red: NES 
>2). 
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Additionally, upregulation of immune system and signal transduction pathways were observed 
(Table 15). 
 
 Differentially expressed KEGG pathways (adj. P-value < 0.05) RNAseq: cisplatin vs control
NES
RNAseq
NF-kappa B signaling pathway 3. Environmental Information Processing 3.2 Signal transduction 1.85
TNF signaling pathway 3. Environmental Information Processing 3.2 Signal transduction 1.93
JAK-STAT signaling pathway 3. Environmental Information Processing 3.2 Signal transduction 1.59
Notch signaling pathway 3. Environmental Information Processing 3.2 Signal transduction 1.79
MAPK signaling pathway 3. Environmental Information Processing 3.2 Signal transduction 1.36
PI3K-Akt signaling pathway 3. Environmental Information Processing 3.2 Signal transduction 1.35
Hippo signaling pathway 3. Environmental Information Processing 3.2 Signal transduction 1.4
Rap1 signaling pathway 3. Environmental Information Processing 3.2 Signal transduction 1.26
Antigen processing and presentation 5. Organismal Systems 5.1 Immune system 1.9
Toll-like receptor signaling pathway 5. Organismal Systems 5.1 Immune system 1.83
Natural killer cell mediated cytotoxicity 5. Organismal Systems 5.1 Immune system 1.93
Leukocyte transendothelial migration 5. Organismal Systems 5.1 Immune system 1.69
Chemokine signaling pathway 5. Organismal Systems 5.1 Immune system 1.72
B cell receptor signaling pathway 5. Organismal Systems 5.1 Immune system 1.68
NOD-like receptor signaling pathway 5. Organismal Systems 5.1 Immune system 1.54
Fc gamma R-mediated phagocytosis 5. Organismal Systems 5.1 Immune system 1.62
Complement and coagulation cascades 5. Organismal Systems 5.1 Immune system 1.59
Platelet activation 5. Organismal Systems 5.1 Immune system 1.49
T cell receptor signaling pathway 5. Organismal Systems 5.1 Immune system 1.5
Th1 and Th2 cell differentiation 5. Organismal Systems 5.1 Immune system 1.91
Th17 cell differentiation 5. Organismal Systems 5.1 Immune system 1.73
C-type lectin receptor signaling pathway 5. Organismal Systems 5.1 Immune system 1.61
IL-17 signaling pathway 5. Organismal Systems 5.1 Immune system 1.46
KEGG pathway Main category Sub category
 
Table 15 GSEA analysis using KEGG database sorted by subcategory: significant (adjusted p-value< 0.05) 
differentially expressed pathways (cisplatin vs control). For each pathway the normalized enrichment score (NES) 
is given. Upregulated pathways are displayed in red (light red: 1.5 >NES> 0; red: 2 >NES> 1.5; dark red: NES 
>2). 
 
 4. Results  -55- 
 
 
 
 
 
4.3.3. ABCB5+ cells/conditioned media effect on gene expression: RNAseq analysis 
 
 
Cluster analysis of 21 RNAseq samples showed that, among the seven experimental groups, 
two distinct clusters could be distinguished. As shown in the heatmap (Figure 26), control 
animals and 2 over 3 animals treated with CM and CM+ clustered together, while all animals 
treated with ABCB5+ cells and coCM+ bunched with the cisplatin-treated animals.  
 
 
Figure 26 Heatmap showing cluster analysis of the experimental groups (n=3 per experimental group) with 
RNAseq. Numbers in the legend correspond to the animal numbers 
 
 
For GSEA analysis, pairwise comparisons of each treatment group to the cisplatin were 
performed. A total of 126 significant (adj p-value< 0.05) differently expressed pathways were 
found. For some pathways, a different trend of expression in the different experimental groups 
was observed. An overview of up and down regulated pathways in the different groups is shown 
in Figure 27. 
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Figure 27 GSEA analysis using KEGG database: number of significant (adjusted p-value< 0.05) upregulated 
(upper figure) and downregulated (lower figure) pathways in the treatment groups. 
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More details can be found in tables 14-17.  
 
Upregulation of xenobiotic degradation and metabolism pathways were found in the animals 
treated with any therapy. Overall, upregulation of several metabolic pathways was mainly 
found in the animals treated with CM and coCM+ (Table 16).  
 Differentially expressed pathways  RNAseq: treatments vs cisplatin
Main category: 1. Metabolism
NES NES NES NES NES
ABCB5 ip ABCB5 iv CM CM+ coCM+
vs cisplatin vs cisplatin vs cisplatin vs cisplatin vs cisplatin
Metabolic pathways 1.0 Global and overview maps 1.34 1.47 2.07 1.62 2.18
Carbon metabolism 1.0 Global and overview maps 1.04 1.02 2.03 1.88 2.25
Biosynthesis of amino acids 1.0 Global and overview maps 0.99 0.71 1.75 1.69 1.9
2-Oxocarboxylic acid metabolism 1.0 Global and overview maps -0.42 0.65 1.53 1.55 1.82
Glycolysis  Gluconeogenesis 1.1 Carbohydrate metabolism 1.08 1.03 1.64 1.69 2.11
Pyruvate metabolism 1.1 Carbohydrate metabolism 1.19 0.94 1.84 1.88 1.98
Glyoxylate and dicarboxylate metabolism 1.1 Carbohydrate metabolism 1.14 0.68 2.28 2.28 2.01
Citrate cycle (TCA cycle) 1.1 Carbohydrate metabolism -0.78 0.67 1.93 1.9 1.96
Pentose phosphate pathway 1.1 Carbohydrate metabolism 1.31 1.43 1.73 1.38 1.92
Amino sugar and nucleotide sugar metabolism 1.1 Carbohydrate metabolism 1.01 0.76 1.33 0.84 1.71
Propanoate metabolism 1.1 Carbohydrate metabolism -0.58 0.54 1.6 1.63 1.74
Ascorbate and aldarate metabolism 1.1 Carbohydrate metabolism 1.67 1.84 2.35 1.61 1.7
Pentose and glucuronate interconversions 1.1 Carbohydrate metabolism 1.77 1.72 2.34 1.46 1.67
Inositol phosphate metabolism 1.1 Carbohydrate metabolism -1.46 0.73 0.92 1.01 -1.38
Fructose and mannose metabolism 1.1 Carbohydrate metabolism 1.09 0.8 1.39 1.79 1.27
Butanoate metabolism 1.1 Carbohydrate metabolism 0.72 -0.74 1.62 1.66 1.1
Drug metabolism (2) 1.11 Xenobiotics biodegradation and metabolism 2.43 2.17 2.42 1.85 2.45
Metabolism of xenobiotics by cytochrome P450 1.11 Xenobiotics biodegradation and metabolism 1.98 1.73 2.38 1.97 2.22
Drug metabolism (3) 1.11 Xenobiotics biodegradation and metabolism 2.08 1.68 2.37 1.86 2.11
Oxidative phosphorylation 1.2 Energy metabolism 1.81 2.03 1.14 -1 2.65
Fatty acid degradation 1.3 Lipid metabolism 1.1 1.1 1.97 1.92 1.9
Linoleic acid metabolism 1.3 Lipid metabolism 1.94 1.56 1.29 0.76 1.93
Arachidonic acid metabolism 1.3 Lipid metabolism 1.63 1.17 1.47 1.29 1.82
Steroid hormone biosynthesis 1.3 Lipid metabolism 1.86 1.54 2.1 1.32 1.72
Fatty acid elongation 1.3 Lipid metabolism 1.21 1.65 1.65 0.87 1.68
alpha-Linolenic acid metabolism 1.3 Lipid metabolism 1.48 1.53 1.23 1.27 1.68
Glycerolipid metabolism 1.3 Lipid metabolism 1.24 1.24 1.76 1.71 1.5
Steroid biosynthesis 1.3 Lipid metabolism 0.96 0.79 1.67 1.13 1.39
Glycerophospholipid metabolism 1.3 Lipid metabolism 1.05 1.59 1.04 0.96 1.18
Biosynthesis of unsaturated fatty acids 1.3 Lipid metabolism 1.2 1.26 1.83 1.4 1.18
Pyrimidine metabolism 1.4 Nucleotide metabolism 1.68 1.73 1.1 -1.08 1.91
Glycine, serine and threonine metabolism 1.5 Amino acid metabolism 1.42 -0.66 2.42 2.15 2.16
Valine, leucine and isoleucine degradation 1.5 Amino acid metabolism 1.09 0.8 1.95 1.79 1.81
Tyrosine metabolism 1.5 Amino acid metabolism 1.24 0.73 1.83 1.57 1.91
Cysteine and methionine metabolism 1.5 Amino acid metabolism 0.89 0.6 1.82 1.58 1.77
Phenylalanine metabolism 1.5 Amino acid metabolism 0.71 -0.67 1.77 1.57 1.62
Tryptophan metabolism 1.5 Amino acid metabolism -0.67 -1.06 2.23 2.19 1.5
Arginine and proline metabolism 1.5 Amino acid metabolism -0.94 -1.29 1.87 1.58 1.42
Alanine, aspartate and glutamate metabolism 1.5 Amino acid metabolism 0.68 -0.7 1.73 1.59 1.24
Histidine metabolism 1.5 Amino acid metabolism -0.74 -1.03 1.96 1.45 1.15
Lysine degradation 1.5 Amino acid metabolism -1.28 -1.03 1.88 1.53 -1.05
Glutathione metabolism 1.6 Metabolism of other amino acids 1.79 1.57 2.06 1.64 2.12
beta-Alanine metabolism 1.6 Metabolism of other amino acids -0.59 -1.49 1.93 1.75 1.43
Selenocompound metabolism 1.6 Metabolism of other amino acids 1.32 1.26 1.86 1.34 1.34
Other glycan degradation 1.7 Glycan biosynthesis and metabolism 1.74 1.43 1.83 1.56 1.78
Mucin type O-glycan biosynthesis 1.7 Glycan biosynthesis and metabolism -1.73 -1.31 0.92 1.11 -1.74
Glycosaminoglycan degradation 1.7 Glycan biosynthesis and metabolism 1.12 0.86 1.59 2.04 1.73
Glycosaminoglycan biosynthesis 1.7 Glycan biosynthesis and metabolism -1.82 -1.57 -1.51 1.3 -1.36
Porphyrin and chlorophyll metabolism 1.8 Metabolism of cofactors and vitamins 1.92 1.6 2.2 1.17 2.04
Retinol metabolism 1.8 Metabolism of cofactors and vitamins 1.48 1.21 2.23 1.24 1.83
One carbon pool by folate 1.8 Metabolism of cofactors and vitamins 0.54 -0.76 1.48 1.18 1.61
Folate biosynthesis 1.8 Metabolism of cofactors and vitamins 1.3 0.72 1.77 1.35 1.3
KEGG pathway Sub sategory
 
Table 16 GSEA analysis using KEGG database sorted by subcategory: significant (adjusted p-value< 0.05) 
differentially expressed pathways (treatment vs cisplatin). For each pathway the normalized enrichment score 
(NES) is given. Downregulated pathways are displayed in green (light green: -1.5 >NES> 0; green: -2 >NES>-
1.5; dark green: NES >-2), upregulated pathways in red (light red: 1.5 >NES> 0; red: 2 >NES> 1.5; dark red: NES 
>2). 
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Translation, proteasome and ribosome biogenesis are unregulated in animals treated with 
ABCB5 cells and coCM+. Additionally, the DNA replication and reparation activity is 
upregulated in ABCB5 cells groups. In contrast, these pathways are downregulated in thje CM 
and CM+ groups (Table 17). 
 
Differentially expressed pathways  RNAseq: treatments vs cisplatin
Main category: 2. Genetic information processing
NES NES NES NES NES
ABCB5 ip ABCB5 iv CM CM+ coCM+
vs cisplatin vs cisplatin vs cisplatin vs cisplatin vs cisplatin
Basal transcription factors 2.1 Transcription 1.36 1.14 -0.95 -1.76 1.03
Spliceosome 2.1 Transcription 1.33 0.79 -1.48 -2.2 -0.64
Ribosome 2.2 Translation 2.74 2.55 -2.02 -2.43 2.22
Aminoacyl-tRNA biosynthesis 2.2 Translation 1.17 1.58 1.18 -0.85 1.68
Ribosome biogenesis in eukaryotes 2.2 Translation 1.47 1.41 0.67 -1.8 1.3
RNA transport 2.2 Translation 1.5 1.27 -0.67 -1.9 0.89
mRNA surveillance pathway 2.2 Translation 1.21 1.17 0.8 -1.62 0.81
Proteasome 2.3 Folding  sorting and degradation 1.97 1.73 -0.85 -1.99 2.02
RNA degradation 2.3 Folding  sorting and degradation 0.83 1.03 -1.24 -1.62 -1.13
Protein export 2.3 Folding  sorting and degradation -0.87 -0.8 -0.69 -1.8 0.71
Protein processing in endoplasmic reticulum 2.3 Folding  sorting and degradation -1.78 -1.26 0.79 -1.39 -0.81
DNA replication 2.4 Replication and repair 1.57 1.39 -0.88 -1.14 1.29
Mismatch repair 2.4 Replication and repair 1.48 1.63 -0.8 -1.34 1.23
Nucleotide excision repair 2.4 Replication and repair 1.56 1.24 -0.84 -1.65 1.11
KEGG pathway Sub sategory
 
Table 17 GSEA analysis using KEGG database sorted by subcategory: significant (adjusted p-value< 0.05) 
differentially expressed pathways (treatment vs cisplatin). For each pathway the normalized enrichment score 
(NES) is given. Downregulated pathways are displayed in green (light green: -1.5 >NES> 0; green: -2 >NES>-
1.5; dark green: NES >-2), upregulated pathways in red (light red: 1.5 >NES> 0; red: 2 >NES> 1.5; dark red: NES 
>2). 
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A strong downregulation of signaling pathways was observed in the animals treated with 
ipABCB56+, ivABCB5+ and coCM+, while no significant changes were found in the CM and 
CM+ groups. Interestingly, the downregulation of the cytokine-cytokine receptor interaction 
pathway was found in all groups (Table 18).  
 
 
Differentially expressed pathways  RNAseq: treatments vs cisplatin
Main category: 3. Environmental information processing
NES NES NES NES NES
ABCB5 ip ABCB5 iv CM CM+ coCM+
vs cisplatin vs cisplatin vs cisplatin vs cisplatin vs cisplatin
MAPK signaling pathway 3.2 Signal transduction -2 -1.88 -1.3 1.18 -1.95
Rap1 signaling pathway 3.2 Signal transduction -2.09 -1.88 -0.97 1.47 -1.83
Calcium signaling pathway 3.2 Signal transduction -1.87 -1.89 -1.33 0.76 -1.77
cGMP-PKG signaling pathway 3.2 Signal transduction -2.22 -2.13 -1.2 1.11 -2.1
cAMP signaling pathway 3.2 Signal transduction -1.8 -1.6 -1.44 0.85 -1.95
PI3K-Akt signaling pathway 3.2 Signal transduction -1.88 -1.84 -0.91 1.17 -1.91
Wnt signaling pathway 3.2 Signal transduction -1.96 -1.61 -1.15 -0.73 -1.89
JAK-STAT signaling pathway 3.2 Signal transduction -1.54 -1.66 -1.19 -0.77 -1.83
TNF signaling pathway 3.2 Signal transduction -1.62 -1.42 -1.69 -1.26 -2.08
Ras signaling pathway 3.2 Signal transduction -1.81 -1.62 -0.96 0.97 -1.68
NF-kappa B signaling pathway 3.2 Signal transduction -1.57 -1.46 -1.84 -1.03 -1.92
FoxO signaling pathway 3.2 Signal transduction -1.46 -1.04 0.78 -0.85 -1.63
Hippo signaling pathway 3.2 Signal transduction -2.23 -1.71 -1.03 1.17 -1.55
Hedgehog signaling pathway 3.2 Signal transduction -1.91 -1.51 0.98 1.6 -1.8
Phosphatidylinositol signaling system 3.2 Signal transduction -1.32 0.82 0.95 1.13 -1.63
Phospholipase D signaling pathway 3.2 Signal transduction -1.57 -1.36 -0.92 1.17 -1.47
HIF-1 signaling pathway 3.2 Signal transduction -1.62 -1.49 -1.43 -0.78 -1.54
Sphingolipid signaling pathway 3.2 Signal transduction -1.58 -1.02 -0.96 -0.68 -1.49
ErbB signaling pathway 3.2 Signal transduction -1.58 0.81 1.05 1.35 -1.54
Hippo signaling pathway 3.2 Signal transduction -1.98 -1.92 -0.9 1.04 -1.64
TGF-beta signaling pathway 3.2 Signal transduction -1.72 -1.15 -0.84 0.91 -1.39
mTOR signaling pathway 3.2 Signal transduction -1.43 0.85 1.06 1.2 -1.28
AMPK signaling pathway 3.2 Signal transduction -1.43 -0.87 1.09 1.28 -1.29
Notch signaling pathway 3.2 Signal transduction -1.51 -1.34 -1.07 1.42 -0.93
Cytokine-cytokine receptor interaction 3.3 Signaling molecules and interaction -1.38 -1.71 -1.94 -1.48 -1.89
ECM-receptor interaction 3.3 Signaling molecules and interaction -1.76 -2.02 -1.27 0.98 -1.93
Cell adhesion molecules (CAMs) 3.3 Signaling molecules and interaction -1.51 -1.27 -1.63 0.79 -1.43
Neuroactive ligand-receptor interaction 3.3 Signaling molecules and interaction -1.14 -1.56 -1.41 0.77 -1.23
KEGG pathway Sub sategory
 
Table 18 GSEA analysis using KEGG database sorted by subcategory: significant (adjusted p-value< 0.05) 
differentially expressed pathways (treatment vs cisplatin). For each pathway the normalized enrichment score 
(NES) is given. Downregulated pathways are displayed in green (light green: -1.5 >NES> 0; green: -2 >NES>-
1.5; dark green: NES >-2), upregulated pathways in red (light red: 1.5 >NES> 0; red: 2 >NES> 1.5;  dark red: NES 
>2). 
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Downregulation of pathways involved in the immune system was mainly observed in the 
ipABCB5+, coCM+ and CM groups. Pathways involved in the regulation of actin cytoskeleton 
and cellular junctions were found downregulated in ipABCB5+, ivABCB5+ and coCM+ (Table 
19). 
 
 
Differentially expressed pathways  RNAseq: treatments vs cisplatin
Main category: 4. Cellular processes - 5. Organismal systems - 6.Human diseases
NES NES NES NES NES
ABCB5 ip ABCB5 iv CM CM+ coCM+
vs cisplatin vs cisplatin vs cisplatin vs cisplatin vs cisplatin
Lysosome 4.1 Transport and catabolism 1.21 1.31 1.69 1.3 1.83
Peroxisome 4.1 Transport and catabolism 1.52 1.49 2.18 1.73 1.83
Endocytosis 4.1 Transport and catabolism -1.35 -0.82 -0.93 1.09 -1.17
Phagosome 4.1 Transport and catabolism -1.12 -1.08 -1.39 -1.26 -0.81
Regulation of actin cytoskeleton 4.2 Cell motility -2.09 -1.81 -1.23 1.1 -2.04
Cell cycle 4.3 Cell growth and death 1.22 1.03 -0.66 -1.6 0.88
Focal adhesion 4.4 Cellular community -2.46 -2.1 -1.09 1.12 -2.25
Signaling pathways regulating pluripot. of stem cells 4.4 Cellular community -1.8 -1.15 -0.96 1.51 -1.64
Adherens junction 4.4 Cellular community -2.16 -1.41 0.7 1.2 -1.78
Gap junction 4.4 Cellular community -1.83 -1.52 -0.88 1.18 -1.55
Tight junction 4.4 Cellular community -1.72 -1.12 -1.08 -0.87 -1.33
Platelet activation 5.1 Immune system -1.89 -1.89 -1.6 -0.76 -2.06
Chemokine signaling pathway 5.1 Immune system -1.65 -1.56 -1.87 -1.15 -2.08
Hematopoietic cell lineage 5.1 Immune system -1.25 -1.51 -1.86 -1.71 -2.01
Natural killer cell mediated cytotoxicity 5.1 Immune system -1.52 -1.48 -1.72 -1.5 -1.98
B cell receptor signaling pathway 5.1 Immune system -1.68 -1.45 -1.74 -1.11 -2.14
Toll-like receptor signaling pathway 5.1 Immune system -1.51 -1.35 -1.64 -1 -2.03
T cell receptor signaling pathway 5.1 Immune system -1.57 -1.19 -1.69 -1.03 -2.24
Fc epsilon RI signaling pathway 5.1 Immune system -1.17 -1.1 -1.55 -0.98 -1.89
NOD-like receptor signaling pathway 5.1 Immune system -1.15 -0.94 -1.56 -1.3 -1.48
Leukocyte transendothelial migration 5.1 Immune system -1.7 -1.34 -1.36 -0.85 -1.5
Complement and coagulation cascades 5.1 Immune system -1.25 -1.88 -1.12 0.93 -1.27
Antigen processing and presentation 5.1 Immune system -1.19 -0.92 -1.63 -0.98 0.93
C-type lectin receptor signaling pathway 5.1 Immune system -1.47 -1.48 -1.74 -1.25 -2.02
Th17 cell differentiation 5.1 Immune system -1.62 -1.36 -1.69 -1.07 -2.1
Th1 and Th2 cell differentiation 5.1 Immune system -1.61 -1.26 -1.78 -0.9 -2.15
IL-17 signaling pathway 5.1 Immune system -1.07 -0.85 -2.06 -1.49 -1.62
Renin secretion 5.2 Endocrine system -1.68 -1.65 -0.73 0.78 -1.72
Renin-angiotensin system 5.2 Endocrine system 0.73 -0.92 2.04 1.11 1.69
Circadian entrainment 5.9 Environmental adaptation -1.54 -1.48 0.75 1.16 -1.7
Circadian rhythm 5.9 Environmental adaptation -1.42 -1.35 0.78 0.88 -1.53
Platinum drug resistance 6.12 Drug resistance: Antineoplastic 1.25 1.56 1.77 1.27 1.26
KEGG pathway Sub sategory
 
Table 19 GSEA analysis using KEGG database sorted by subcategory: significant (adjusted p-value< 0.05) 
differentially expressed pathways (treatment vs cisplatin). For each pathway the normalized enrichment score 
(NES) is given. Downregulated pathways are displayed in green (light green: -1.5 >NES> 0; green: -2 >NES>-
1.5; dark green: NES >-2), upregulated pathways in red (light red: 1.5 >NES> 0; red: 2 >NES> 1.5;  dark red: NES 
>2) 
 
 
 4. Results  -61- 
 
 
 
 
 
4.4.  miRNA expression analysis 
 
Thanks to the ability of RNAseq technology to detect miRNAs, we were able to perform 
miRNA expression analysis on renal tissue obtained from sacrificed animals.  
 
 
 
4.4.1. Cisplatin effect on miRNA expression 
 
miRNA expression analysis was performed according to the workflow shown in Figure 28.  
 
  
 
Figure 28 miRNA expression analysis: workflow 
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In the cisplatin treated animals, the expression of 14 miRNAs was found significantly changed 
(adj. p<0.05); 6 miRNAs were downregulated, whereas 8 were upregulated (Table 20). 
miRNA Log2FC miRNA Log2FC
mir-5132 -2.79 mir-3120 2.97
mir-1199 -2.58 mir-155 2.87
mir-196b -1.99 mir-214 2.83
mir-6321 -1.78 mir-142 2.71
mir-10a -0.98 mir-147 2.32
mir-3064 -0.58 mir-6328 1.78
mir-21 1.69
mir-678 1.34
Log2 fold change (cispaltin/control)
of differentially expressed miRNAs  (p<0.05)
Downregulated miRNAs Upregulated miRNAs
 
Table 20 List of significant differentially expressed miRNAs (p<0.05) obtained with RNAseq analysis. Log2 fold 
change (Log2FC) of cisplatin vs control is shown. 
 
 
The top five upregulated (mir-5132, mir-1199, mir-196b, mir-6321, mir-10a) and 
downregulated (mir-3120, mir-155, mir-214, mir-142, mir-147) miRNAs were selected for the 
subsequent analysis. By using the miRWalk program with a cutoff of binding p value=1, the 
putative target genes of the 10 aforementioned miRNAs were predicted.  
The analysis showed 6192 and 5196 target genes of the five top downregulated and upregulated 
miRNAs respectively. The putative genes were compared with the 6333 significant (adj. 
p<0.05) differentially expressed genes found in the RNAseq analysis. Genes in common 
between the two groups were selected.  
As a result, 2185 and 1898 overlapping genes of the downregulated and upregulated miRNAs 
respectively were selected and used for the further analysis (Figure 29).  
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Figure 29 Selection of top 5 downregulated and upregulated miRNAs target genes. The Venn diagrams show the 
intersection between the putative target genes obtained by miRWalk and the differentially expressed genes found 
with RNAseq. Genes in common between the two groups were selected. 
 
 
To elucidate their biological functions, the selected miRNA target genes where analyzed with 
the DAVID program, where BP-GO analysis was performed. The top 5 downregulated and 
upregulated miRNA selected target genes resulted in 290 and 207 significant (p<0.05) BP-GO 
terms respectively. Only terms of interest with a cutoff of adj. p value≤0.1 were selected. 
However, being the term GO:0043065 (positive regulation of apoptotic processes) of interest 
for our study, it was added to the list, albeit it had an adj. p value=0.11. All selected GO terms 
are shown in Table 21 
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Gene Percentage adj. p value
count covered (FDR)
GO:0030335~positive regulation of cell migration 52 2.4 0.00
GO:0010628~positive regulation of gene expression 72 3.3 0.00
GO:0014070~response to organic cyclic compound 55 2.5 0.02
GO:0008285~negative regulation of cell proliferation 69 3.2 0.03
GO:0071456~cellular response to hypoxia 33 1.5 0.05
GO:0045944~positive regulation of transcription from RNA polymerase II promoter 153 7.0 0.08
GO:0043065~positive regulation of apoptotic process 62 2.8 0.11
Gene Percentage adj. p value
count covered (FDR)
GO:0030335~positive regulation of cell migration 43 2.3 0.00
GO:0006468~protein phosphorylation 80 4.2 0.02
GO:0042493~response to drug 83 4.4 0.02
GO:0001822~kidney development 33 1.7 0.03
GO:0008285~negative regulation of cell proliferation 62 3.3 0.07
GO:0034162~toll-like receptor 9 signaling pathway 6 0.3 0.09
Term
Downregulated miRNAs target genes involved in BP-GOs 
Upregulated miRNAs target genes involved in BP-GOs 
Term
 
Table 21 Involvement of significant differentially expressed miRNA target genes in BP-GO terms (adj. p value 
≤0.1; GO0043065 adj. p value=0.11). miRNA target genes and BP-GO terms were obtained with the miRWalk 
and DAVID programs respectively. For each BP-GO term, the number and the percentage of genes counted are 
given. Adj. p value is also reported 
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4.4.2. ABCB5+ cells/conditioned media effect on miRNA expression 
 
ABCB5+ cells and derived conditioned media also affected miRNAs expression. The analysis 
was performed by following the workflow shown in Figure 28. Table 22 illustrates the 
differentially expressed miRNAs found in the different groups. 6 differentially expressed 
miRNAs were found in ipABCB5+ treated animals (downregulated: miR-7a-1, miR-632; 
upregulated: miR-3562, miR-3596b, miR-let-7d, miR-3594), 6 in CM+ (downregulated: miR-
147, miR-155, miR-7a-1; upregulated: miR-5132, miR-196b, miR-3594), 2 in CM 
(upregulated: miR-5132, miR-186) and 1 in coCM+ (downregulated: miR-142) and ivABCB5+ 
(upregulated: miR-6318). Five over 14 differentially expressed miRNAs found in the cisplatin-
induced nephrotoxicity model were found oppositely regulated in animals treated with CM 
(miR-5132), coCM+ (miR-142) and CM+ (miR-5132, miR-196b, miR-147, miR-155). 
 
miRNA cispaltin model ipABCB5+ ivABCB5+ CM CM+ coCM+
miR-5132 -2.79 1.96 1.91
miR-196b -1.99 0.93
miR-147 2.32 -1.50
miR-142 2.71 -1.21
miR-155 2.87 -1.46
miR-7a-1 -1.59 -1.46
miR-186 1.26
miR-6318 0.99
miR-632 -1.73
miR-3562 0.88
miR-3596b 1.30
miR-let-7d 1.30
miR-3594 2.36 2.22
Log fold change of significant differentially expressed miRNAs  (p<0.05) 
in cisplatin model (cisplatin/control)  and treated animals (treatment/cisplatin)
LogFC
 
Table 22 List of significant differentially expressed miRNAs (p<0.05) obtained with RNAseq analysis. Positive 
and negative log fold change (LogFC) values are displayed in red and green respectively. 
 
 
 
 
We checked for putative target genes of the miRNAs and we selected only the ones that overlaps 
with the differentially expressed genes found in each experimental group by RNAseq gene 
expression profiling. An overview is reported in Table 23. 
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Downregulated Upregulated Sign (adj p<0.05) Downregulated Upregulated 
Treatment miRNA  miRNA differentially miRNA  selected miRNA  selected 
target genes target genes  expressed genes target genes target genes
Iv ABCB5+ - 1988 23 - 2
Ip ABCB5+ 1658 6530 13 0 2
CM - 4310 419 - 91
CM+ 2410 6266 85 7 28
coCM+ 677 - 15 - 0  
Table 23 Number of miRNAs target genes before and after selection. Putative target genes, obtained with the 
miRWalk program, were compared with the significant differentially expressed genes found with RNAseq 
analysis. Only overlapping genes were selected 
 
 
 
As result, only upregulated miRNAs found in CM treated animals showed a sufficient number 
of selected target genes to perform BP-GO analysis, which was carried out by using the DAVID 
database. The analysis did not show any significance at the adjusted but only at the nominal p 
value (p<0.05). The obtained BP-GO terms are reported in Table 24. 
Gene Percentage
count covered
GO:0055114~oxidation reduction 10 1.5 0.00
GO:0009611~response to wounding 6 0.9 0.03
GO:0044271~nitrogen compound biosynthetic process 6 0.9 0.01
GO:0006631~fatty acid metabolic process 5 0.7 0.01
GO:0006732~coenzyme metabolic process 4 0.6 0.03
GO:0001655~urogenital system development 4 0.6 0.03
GO:0016053~organic acid biosynthetic process 4 0.6 0.03
GO:0046394~carboxylic acid biosynthetic process 4 0.6 0.03
GO:0009309~amine biosynthetic process 4 0.6 0.01
GO:0043648~dicarboxylic acid metabolic process 4 0.6 0.00
GO:0030308~negative regulation of cell growth 3 0.4 0.04
CM treated animals
Upregulated miRNAs target genes involved in BP-GOs 
Term p value
 
Table 24 Involvement of upregulated miRNA target genes in BP-GOs terms (p value<0.05). miRNA target genes 
and BP-GO terms were obtained with the miRWalk and DAVID programs respectively. For each BP-GO term, 
the number and the percentage of genes counted are given. p value is also reported 
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4.5.  Cytokines assay on conditioned media  
 
By using an ELISA array, conditioned media were tested for the following 12 cytokines: IL2, 
IL4, IL5, IL6, IL10, IL12, IL13, IL17A, IFNγ, TNFα, G-CSF, TGFβ1. The result showed 
changes among the groups in TGFβ1, TNFα, IL6 and G-CSF levels. IL6 and G-CSF levels were 
higher in coCM+ compared to the other conditioned media. Higher levels of TGFβ1 and TNFα 
were found in M+ when compared to the other conditioned media (Error! Reference source 
not found.). 
 
 
 
Figure 30 ELISA of 4 secreted cytokines: IL6, TNFα, G-CSF and TGFβ1. Data are corrected for the negative 
control and adjusted for the dilution factor. All samples were assayed in duplicate and values are shown are 
means ± SD from 2–3 independent tests 
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5. Discussion 
 
 
Nowadays, stem cells therapy represents the most promising approach for the treatment of 
several pathologies in different medical fields, including nephrology. Several studies described 
the application of different types and sources of stem cells for treating various renal diseases 
but up to now, no consensus about the best source, type, dose and administration route to be 
used has been achieved. 
The aim of this study was to test the therapeutic potential of human skin derived ABCB5+ cells 
and different cell-derived conditioned media on renal injury.  
For this purpose, a stable model of cisplatin-induced kidney damage was established in 
immunocompetent rats. The progression of the renal damage was evaluated by periodically 
measuring plasmatic and urinary parameters, performing transcutaneous assessment of renal 
function and checking the metabolic parameters. The established model was then used to test 
the therapeutic potential of ABCB5+ cells and different cell-derived conditioned media. 
This study has demonstrated that ABCB5+ derived conditioned medium (CM) showed 
therapeutic potential both at functional and genomic level in treating cisplatin-induced 
nephrotoxicity.  
 
 
5.1. Cisplatin-induced nephrotoxicity model in immunocompetent SD rats 
 
Kidney failure in immunocompetent SD rats was induced by cisplatin, the nephrotoxic side 
effect of which is well known and documented 36, 58. Although cisplatin has been used for 
decades to establish kidney injury in animal models, there is no apparent agreement about the 
dose that has to be used to induce the damage or about the evaluation points that have to be 
chosen for monitoring the disease progress 39. What is known is that the severity of cisplatin-
induced damage is dose and time dependent 59, 60. Previous studies have shown that a single ip 
dose of cisplatin was sufficient to induce renal impairment and that the maximum stage of 
tubular necrosis was reached 7 days after cisplatin administration 61, 62. In this study, a single ip 
dose of 7mg/kg BW was chosen and evaluations were made before cisplatin administration and 
2, 7 and 14 days after.  
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Although injecting cisplatin in the peritoneum could appear an easy procedure to perform, 
several issues regarding both the handling and the administration of cisplatin have been 
encountered.  
Indeed, platinum drugs are known to be relatively poorly soluble and choosing the best solvent 
and drug concentration is of high importance. As shown in Figure 2, cisplatin becomes active 
in the intracellular low chloride environment after replacing one or both of its chloride ligands 
with water molecules, a phenomenon known as `aquation´ 19.   For this reason, cisplatin has to 
be dissolved in saline solution with a high chloride concentration in order to prevent its aquation 
prior to administration. Solvents like DMSO, which reacts with cisplatin forming various 
complexes, or PBS, which provides an alkaline environment that leads to the hydrolysis of the 
drug, have to be avoided 63. Another important aspect to take into account is the light sensitivity 
of cisplatin, which makes simple routine actions, such as weighing the drug on a scale, more 
complicated. Therefore, it is recommended to dissolve cisplatin in saline solution to a final 
concentration of 0.5 mg/ml, avoiding working under direct light.  After failing several times in 
inducing kidney injury in our animals, probably because of an incorrect handling and/or 
solubilization of the drug, we decided to use a ready-to-use cisplatin solution provided by the 
company TEVA 64.  
To induce renal damage in rodents, cisplatin is usually ip administrated. Although it seems a 
simple procedure, ip injection needs to be precisely performed in order not to puncture vital 
organs such as the cecum, which causes pain and sometimes peritonitis. Moreover, if cisplatin 
is administrated intra-caecum rather than ip, animals do not develop kidney injury. It is known 
that the cecum is most commonly located in the left part of the abdominal cavity. However, a 
study conducted on rats has demonstrated that the position of the caecum varies among species, 
litters and gender 65. Therefore, a correct ip injection represents a critical point for the induction 
of renal damage. In order to overcome a possible intra-caecum puncture, we decided to perform 
ip injection under short isoflurane anesthesia and by using a butterfly cannula rather than a 
normal needle. In this way, while the animal is lying on its back, we could lift the abdominal 
wall and introduce the cannula under the skin fold. A free movement of the cannula was the 
sign that we were in the peritoneum and that we could then inject the drug. Eventually, after 
several trials, we were able to perform a correct ip injection.   
 
 5. Discussion -70- 
 
 
 
 
 
For monitoring the progression of the disease, blood and urine parameters were analyzed.   
Plasma creatinine and urea are worldwide accepted as gold standard markers of renal damage, 
even though several studies showed that their levels were not always found altered at the same 
stage of the disease. Indeed, some previous studies showed increased plasma creatinine and 
urea levels detectable already 2 days after cisplatin administration 66, while in other studies they 
were not detectable until 5 days after cisplatin administration 60. Notably, it has to be also taken 
into account that plasma creatinine lacks sensitivity and its level can also be affected by non-
renal factors such as gender, age, physical activity, muscle mass and liver function 67-70. The 
experiment performed here showed that the single intraperitoneal dose of cisplatin used was 
sufficient to induce renal damage. Indeed, already 2 days after the administration of cisplatin, 
animals showed a 1.6 and 2-fold increase of plasma creatinine and urea respectively when 
compared to the healthy not treated animals. These parameters remain altered until the end of 
the experiment, with a peak on day 7 when an increase of 7.6-fold for creatinine and 7.5-fold 
for urea was observed (Figure 7).  
 
Other plasma parameters, which were found altered in this model, were cholesterol and 
triglycerides. Cholesterol increased by 1.4-fold compared to the control animals already on day 
2 and it remained high until the end of the experiment.  Differently, triglycerides halved on day 
2 and then increased in the following days, by reaching a 1.2-fold increase on day 14 in the 
cisplatin-treated animals compared to the time-matched controls (Figure 8). 
Hypercholesterolemia and hyperlipidemia had been previously described in cisplatin-treated 
rats 71 and it has been explained as a consequence of the excessive production of reactive oxygen 
species during the induced damage 35. Additionally, accumulation of cholesterol in kidney 
affected by renal injury was seen and it has been proposed to be part of a “renal stress response” 
72, 73 . 
 
Electrolyte deficiencies after cisplatin treatment were widely described in literature 74, 75. We 
analyzed plasma and urinary levels of calcium, potassium, sodium and phosphate, 
unfortunately, we did not measure magnesium.  It is known that cisplatin induces renal 
magnesium wasting which can lead to hypocalcemia and hypercalciuria 76. We observed an 
early hypocalcemia on day 2 and a following hypercalcemia on day 7 and 14. Hypercalciuria 
was observed on day 14. Being magnesium a cofactor of ATP, hypomagnesemia leads to 
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potassium and phosphate wasting 74, 77. In this model, hypokalemia, hypophospaturia and a 
marked decrease in urinary potassium was detected on day 2. Hypophosphaturia was observed 
on day 14. In contrast to the other electrolytes wasting, sodium level remained stable in both 
urine and plasma (Figure 9).  
 
In this model, urine analyses showed no proteinuria, even though kidney injury is usually 
associated with a loss of proteins. Previous studies in rats have shown proteinuria 4/5 days after 
cisplatin administration, which resolved spontaneously in the next days 60, 61. Therefore, it could 
be possible that there was proteinuria between day 2 and 7 but was not detected. Conversely, 
abundant albuminuria, which is typically associated to proximal tubular dysfunction 78, was 
recorded from day 2 onwards with respect to the corresponding controls. Damaged proximal 
tubular cells also fail in reabsorbing glucose, leading to glycosuria 79. In our model, urinary 
glucose level progressively increased by 17.2-fold on day 7 until 26.8-fold on day 14. 
Glycosuria was not associated to glycemia, accordingly with the typical scenario of tubular 
dysfunction (Figure 11).  
 
Urine volume is another parameter that has to be considered when referring to kidney injury.  
Polyuria, indeed, was already largely described in literature as a consequence of cisplatin 
therapy 80. In the model here described, diuresis triplicated on day 7 and visibly remained high 
until the end of the experiment, along with a significant increase of water intake from day 7 
onwards (Figure 14).  
 
Concerning BW, it is well known that cisplatin induces anorexia 81. Accordingly, already 2 days 
after cisplatin administration, animals decreased the amount of food intake, which was reflected 
by a decrease in weight gain on day 7 and 14. While control animals progressively gained 
weight, cisplatin-treated animals visibly appeared more fatigued and weaker than the time-
matched controls (Figure 15).  
 
Besides its well documented nephrotoxic effect, cisplatin-induced hepatotoxicity has also been 
reported 82, 83. To test whether in our model cisplatin affects liver, plasma levels of the hepatic 
enzymes were also measured. In a previous study 84 , increased plasma levels of AST and ALT 
were recorded in rats already 2 days after cisplatin administration. Differently, we observed a 
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reduction in AST levels on day 2 in the treated animals compared to the controls, which was 
probably due to outliers in the control group. No differences were observed in ALT and GGT 
levels. However, we observed an increase by 2.5-fold on GDHL levels on day 7 but the result 
was not statistically significant (Figure 10). A possible explanation to this apparently 
incongruent result could be addressed to the cisplatin dose used in our experiment. Indeed, 
significant increases of hepatic enzymes were found in studies in which high doses of cisplatin 
were used. In oncology, the cisplatin dose that can be administrated for cancer therapy has to 
be low to minimize the nephrotoxic side effect, which usually occurs at a lower dose than the 
one which could lead to hepatotoxicity 82. Therefore, we probably did not see severe changes 
in liver enzymes because we did not use a very high cisplatin dose, apparently needed for liver 
damage.  
 
Besides plasma and urine analyses, the progress of the diseases was also evaluated by a 
transcutaneous measurement of renal function 51, 52, 54. Briefly, the ABZWCY-HPβCD 
fluorescent dye was iv injected into the animals and its excretion curve was transcutaneously 
measured with a specific device. Nowadays, this represents an innovative, precise, not invasive 
analysis for measuring the renal function. The results indicate that ABZWCY-HPβCD half-life 
in healthy rats of this strain is between 32 to 39 minutes. Data showed that already 2 days after 
cisplatin administration, ABZWCY-HPβCD half-life increased by 1.8-fold, and doubled after 
14 days, indicating that the renal function is extremely compromised (Figure 13).   
 
Histological kidney sections also showed the nephrotoxic effect of cisplatin. Indeed, it is well 
known that cisplatin accumulates in the renal proximal tubules, where it causes the main 
damage 26, 32, 85, 86. Accordingly to what is described in literature 84, 87, we observed the expected 
histological changes due to cisplatin treatment, with predominant proximal tubular 
degeneration and formation of casts in the lumen due to proteins and detached tubular cells 
(Figure 16 and Figure 17). We did not observe cisplatin-induced glomerular damage, which 
could be recorded after long-term exposure to cisplatin 88, 89.  
 
Gene expression analysis was performed with RNAseq technology. To the best of our 
knowledge (NCBI GEO Series, keyword: cisplatin, 
https://www.ncbi.nlm.nih.gov/geo/browse/?view=series&search=cisplatin&tax=10116&zsort
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=date&display=20), this is the first study that analyzed changes in gene expression in a 
cisplatin-induced nephrotoxicity model in SD rats by using RNAseq. 
Cluster analysis showed that the two experimental groups distinctly clustered and showed 6333 
differentially expressed genes in the cisplatin treated animals when compared to the controls. 
The GSEA analysis, which analyzes sets of genes describing pathways, revealed 49 significant 
differentially expressed pathways in the cisplatin treated animals when compared to the 
controls.  
 
We observed that cisplatin promoted the upregulation of apoptosis and p53 signaling pathways, 
which lead to tissue degeneration (Table 13). In line with our result, the activation of p53 after 
cisplatin administration and the consequent increase of caspase cascade that leads to apoptosis 
has been largely described in literature 90-94. Cisplatin-induced up-regulation of death receptors 
and their ligands, such as TNFR1, TNFR2, TNFα, Faslg and Fas, which are responsible for the 
extrinsic pathway of the programmed cell death, has also been reported 95-97. Accordingly, in 
our model all the aforementioned receptors and ligands were found upregulated. 
 
TNFα plays an important role during cisplatin-induced nephrotoxicity, not only in terms of 
apoptosis induction, but also in relation to inflammation, due to its ability to activate pro-
inflammatory molecules 95, 98. Indeed, we found upregulated pathways related to cytokine and 
chemokine activity. Furthermore, our model showed upregulation of immune system pathways, 
such as leucocytes recruitment and activation, indicating an ongoing inflammatory response. 
Accordingly, we also observed immune cells infiltrate in the kidney histological sections 
(Figure 16 and Figure 17).  
 
As reported in literature, also the renin-angiotensin system (RAS) was affected by cisplatin 
(Table 13). Indeed, beside the well-known circulatory RAS, it has also been identified an intra-
tubular RAS 99-102. As mentioned before, we know that cisplatin selectively accumulates in the 
proximal tubular cells, where it triggers apoptosis. As we expected, in our cisplatin-induced 
nephrotoxicity model we observed a downregulation of the renal RAS due to tubular cell death. 
Changes in the cell cycle of renal cells after cisplatin administration have also been investigated. 
It is known that after DNA damage, p53 induces the expression of p21, which interacts with 
cdk2 and causes G1 phase arrest 103. Accordingly, in our model we found an upregulation of 
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the cell cycle pathway, where both p53 and p21 appear to be highly upregulated (Table 14). 
Worthy to be mentioned, a p53-independent activation of p21 has also been reported 104. Studies 
have demonstrated that the activation of p21 after cisplatin administration is a protective 
strategy that kidney cells apply to avoid DNA-damaged cells from entering the cell cycle 105, 
106.  
 
Concerning signaling activity, several pathways, such as MAPK, JAK/STAT, NFkB, PI3K-
AKT, which are known to be involved in the regulation of apoptosis, cell cycle, immune cell 
recruitment and cell interaction, were found upregulated (Table 15). Changes in the regulation 
of these pathways in relation to cisplatin-induced nephrotoxicity have been largely investigated 
for decades 107-111.  
 
Pathways related to metabolism, including carbon, fatty acid, amino acid and oxocarboxylic 
acid metabolic pathways, were found downregulated (Table 13). A possible explanation could 
be the cisplatin-induced cell death, which is also evident in the histological sections, where the 
nude basal membrane of the tubuli is clearly visible. The only metabolic pathway found 
upregulated in our model is the one relating to the glycosaminoglycan (GAG) biosynthesis. 
GAGs are polysaccharides that can be expressed on the cell surface or be part of the ECM. By 
interacting with many different proteins, GAGs can be involved in several biological functions 
involving tissue development and homeostasis 112, 113. GAGs are well known to take part in the 
wound healing process, during which  the degraded tissue is replaced with a new functional one 
114. Therefore, we assume that these molecules are conducting an ongoing regenerative process. 
Indeed, it has to be taken into account that we are analyzing the gene expression profile of renal 
tissue 14 days after cisplatin administration and that, at that time, a regenerative process can 
occur. Supporting this hypothesis, several pathways involved in DNA replication, ribosome and 
spliceosome assembly, ECM remodeling and cell junctions were also found upregulated.  
 
The GSEA results described so far seem to define two different phenomena happening in the 
kidney at the same time: tissue degeneration, due to cisplatin, and tissue regeneration, due to 
the kidney intrinsic self-recovery ability 115. Nowadays, it is still poorly understood what 
mediates the renal regeneration, but the latest results address this ability to the renal epithelium 
cells that have survived the injury and that can either transdifferentiate in other cells or 
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dedifferentiate and acquire mitotic properties 116-118. The role of the immune system, mainly 
dendritic cells and M2 macrophages, has also been addressed to induce renal regeneration 119-
122.  
 
Besides the mRNA expression profiling just described, RNAseq technology also allows to 
perform miRNAs expression analysis. Indeed, we were able to identify miRNA precursors 
differentially expressed in our model, which can be used to predict their putative targets. 
miRNAs are involved in the post-transcriptional regulation of gene expression and a single 
miRNA can regulate hundreds of genes 123-125. Understanding the link between miRNA and 
cisplatin-induced kidney injury would be of great importance and the scientific community has 
already started focusing on that direction. Some studies have already identified some miRNAs 
related to cisplatin-induced nephrotoxicity. These miRNAs were mainly involved in the 
regulation of apoptosis and cell cycle 126-128. In our model, 6 downregulated (mir-5132, mir-
1199, mir-196b, mir-6321, mir-10a, mir-3064) and 8 upregulated (mir-3120, mir-155, mir-214, 
mir-142, mir-147, mir-6328, mir-21, mir-678) miRNAs were found (Table 20) and among 
them, mir-155 had already been associated with cisplatin-induced nephrotoxicity 129. In order 
to have an idea of the miRNA-mRNA networks involved in our model, miRNAs target genes 
were predicted and combined with the differentially expressed genes found in the mRNAs 
analysis. The intersection of these two groups of genes were used for functional annotation 
analysis (Figure 29). The BP-GO analysis revealed the involvement of the top 5 downregulated 
miRNAs in the regulation of cell migration and proliferation, apoptosis, transcription and 
regulation of gene expression. BP-GO terms found for the top 5 upregulated miRNAs were 
mainly involved in the regulation of cell migration and proliferation, response to drugs, kidney 
development and toll-like 9 signaling pathway, an immune-system related pathway (Table 21).  
 
Overall, taking into account all the functional, morphological and genetic changes described so 
far, we can assume that the cisplatin-induced nephrotoxicity model was successfully established 
and could be used for the application and evaluation of new therapies.  
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5.2. Therapeutic effect of ABCB5+ cells and conditioned media in cisplatin-
induced nephrotoxicity model in SD rats 
 
The cisplatin-induced nephrotoxicity model, which we previously established and described, 
was used to test the therapeutic potential of stem cells and conditioned media. Indeed, in the 
last decades, stem cells have been largely used as a possible treatment for several pathologies 
in different medical fields and encouraging results have been achieved 130. In nephrology, 
different cell types and sources have been used but, up to now, no consensus about what is best 
to be used has been reached 40. In our study, we decided to use a subpopulation of human dermal 
stem cells characterized by the expression of the ABCB5 peptide on their membrane 49. These 
cells represent a particular non-hematopoietic lineage cell subset that shows immune-regulatory 
functions similar to stem cells. ABCB5+ cells were purified from skin of healthy individuals of 
different sex, age and nationality by Ticeba-RHEACELL and were delivered as a ready-to-use 
solution. In our cisplatin-induced nephrotoxicity animals, ABCB5+ cells were administrated 
not only iv, but also ip. Indeed, one of the major concerns regarding the iv administration route 
is that the injected cells might be trapped within the lung and could provoke embolism, which 
can lead to death 131-133. To overcome this problem, beside the common iv administration, we 
decided to additionally test the ip cell administration and to compare the outcomes obtained by 
the two administration routes.  
 
We analyzed the same plasma and urine parameters we checked for the model characterization 
but, surprisingly, no differences were observed between the cell treated and untreated animals. 
All parameters remained relatively constant, indicating that no amelioration was achieved by 
using the cells (Table 7, Table 8). Similarly, no improvement was observed when the BW and 
the food intake were evaluated (Table 10). Additionally, histology of kidney section did not 
show any visible amelioration after cell administration (Figure 23). Moreover, the 
transcutaneous measurement of renal function showed an ABZWCY-HPβCD half-life even 
higher than the one of the cisplatin-treated animals, indicating that the ABCB5+ treatment even 
worsened the animals’ renal function (Table 9). 
 
To investigate the genetic effects induced by ABCB5+ cell administration on kidney, we 
performed gene expression profiling of renal tissue and GSEA analysis. Overall, some 
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differences between animals treated with the two different administration routes were observed 
when compared to the cisplatin-treated animals. The analysis revealed that downregulation of 
pathways involved in signal transduction were found in both groups but mostly in the 
ipABCB5+ one, evidencing that the treatments took action at the genetic level and had some 
effects on cell growth, metabolism, proliferation and immune system response. 
Metabolic pathways regarding carbohydrate, lipid and nucleotide metabolism were upregulated 
in both groups (Table 16). Upregulation of DNA replication and repair in ipABCB5+ group, 
and upregulation of ribosome and proteasome activity in both groups were also observed, 
indicating that new cells were developing (Table 17). 
We did not observed any difference in the RAS expression but we recorded an upregulation of 
the renin secretion pathway in both groups (Table 19). Accordingly, signaling pathways 
involved in renin synthesis, such as cAMP, cGMP and calcium signaling pathways, were also 
found downregulated (Table 18).   
In both groups, but mainly in the animals treated with ipABCB5+ cells, immune system 
pathways were found downregulated, signifying that inflammation was attenuated (Table 19).  
Conversely, in animals treated with ipABCB5+, upregulation of pathways regarding ECM 
remodeling and cell adhesion were found downregulated, indicating that the tissue was not 
regenerating (Table 18). In support of this thesis, glycan degradation and downregulation of 
their biosynthesis was also found in ipABCB5+ group (Table 16).  
Overall, the analysis indicated that the ipABCB5+ cell treatment displayed a higher reduction 
of inflammation than the ivABCB5+ cell one. The ip treatment also showed new cell formation, 
which was not associated to tissue remodeling.  
 
miRNA analysis was also performed. Six significant differentially expressed miRNAs were 
found in ipABCB5+ treated animals (downregulated: miR-7a-1, miR-632; upregulated: miR-
3562, miR-3596b, miR-let-7d, miR-3594) and only one in ivABCB5+ (upregulated: miR-
6318). None of these miRNAs was found in the cisplatin model (Table 22). However, the 
intersection of predicted miRNA target genes with differentially expressed genes did not give 
a sufficient number of genes to perform BP-GO analysis (Table 23). 
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The results just discussed revealed that even though we have not been able to see any 
amelioration in the plasma and urine parameters, in the renal function and in the histology, 
animals treated with ABCB5+ cells underwent genetic changes.  
 
 
In the last decades, the scientific community has mostly focused its attention to the stem cell 
secretome, assuming that the therapeutic potential of stem cells is not due to the cells themselves 
but it is more ascribed to what they release in the medium where they grow 46. Therefore, a 
paracrine therapeutic effect of stem cells has been proposed 44, 45. In the light of this and seen 
the weak results achieved with the administration of ABCB5+ cells, we decided to use 
conditioned medium of ABCB5+ cells as an alternative therapy for the treatment of cisplatin-
induced kidney injury. Conditioned medium from ABCB5+ cell culture was collected and 
referred as CM.  
A previous study has demonstrated that local injection of ABCB5+ cells around a wound 
accelerates the healing process by promoting the macrophage polarization from a M1 pro-
inflammatory to a M2 anti-inflammatory phenotype via paracrine release of IL-1RA (Ticeba, 
personal communication). The study asserted that ABCB5+ cells have immune-modulatory 
effects on macrophages by inducing their polarization into the M2 anti-inflammatory 
phenotype. Based on this data, ABCB5+ cells were co-cultured with macrophages and both 
cells were stimulated with LPS and IFNγ, known factors for macrophages polarization 
triggering 134. The medium conditioned by the co-culture was collected and called coCM+. To 
test a possible effect of LPS and IFNγ on ABCB5+ cells, we also cultured and stimulated 
ABCB5+ cells without macrophages and we collected the derived conditioned medium, which 
was referred as CM+. 
Thereby, the therapeutic potential of the three aforementioned conditioned media, CM, CM+ 
and coCM+, was tested in our cisplatin-induced nephrotoxicity model, yielding promising 
results.  
 
Especially on day 7, we observed a noteworthy reduction of plasma creatinine and urea in 
animals treated with CM and CM+. More precisely, creatinine decreased by more than 4 and 2 
times while urea by 3 and almost 2 times in animals treated with CM and CM+ respectively 
when compared to the cisplatin treated group (Figure 18). On day 14, albuminuria was 
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ameliorated in animals treated with all the conditioned media (Figure 20), while glycosuria was 
highly decreased only in CM treated animals (Figure 21). Regarding the hepatic enzymes, 
GLDH levels decreased on day 7 by almost 4 and 3 times in animals treated with CM and CM+ 
respectively (Figure 19). Oddly, the increase of plasma triglycerides observed on day 7 on in 
our model, seems to be exacerbated in animals who received CM. Between day 2 and 7, which 
represents the critical time span when cisplatin treated animals loose gaining BW, animals who 
received CM+ maintained a quite stable BW, while the ones who received CM even gained 
weight. At the same time, the food intake in CM and CM+ treated animals was higher than in 
the control and coCM+ treated groups. Moreover, loss of weight gain was recorded between 
day 2 and 7 in animals who received coCM+ (Table 10). Renal function transcutaneously 
measured on day 7 and 14 showed that animals treated with CM and CM+ had faster 
ABZWCY-HPβCD excretion when compared with the cisplatin-treated animals (Table 9). 
Additionally, in CM treated animals, the histological results revealed a less severe damage in 
terms of affected area and protein casts accumulation. Indeed, this group presented proximal 
tubule damage mainly in the juxtamedullary region rather than in the whole corticomedullary 
region (Figure 23). 
 
To investigate the genetic effects induced on kidney by conditioned media administration, we 
performed gene expression profiling of renal tissue and GSEA analysis. The analysis revealed 
pronounced differences among the treatments.   
Indeed, we observed 20 downregulated pathways involved in signal transduction in coCM+ 
treated animals and only 6 of them, such as, TNFα, MAPK and NFkB pathways, in the CM 
group when compared to the cisplatin-treated animals (Table 18). Interestingly, the CM+ group 
seemed not to be significantly affected at the signaling level, where we only observed the 
upregulation of Rap1 pathway, which is involved in cell adhesion. Accordingly, pathways 
regarding ECM and cell adhesion were mainly found downregulated in coCM+ but not in CM+ 
treated animals (Table 18). Following the same trend, immune system pathways resulted 
significantly downregulated in CM and coCM+ treated animals but not in the CM+ group 
(Table 19).  
Therefore, the first conclusion we can draw from these results is that in CM and coCM+ treated 
animals we observe a downregulation of signal transduction that mainly reflects a decrease in 
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the inflammatory process, while CM+ treated animals showed no significant changes compared 
to the cisplatin treated animals.  
Concerning tissue metabolism, pathways regarding carbohydrate, lipid and amino acid 
metabolism were upregulated in all groups, but mainly in CM and coCM+ (Table 16). Also the 
RAS pathway, which was found downregulated in our model, was upregulated in CM and 
coCM+ treated animals, indicating tubular activity (Table 16).  
In coCM+ treated animals, the pronounced activation of the metabolism, the upregulation of 
the proteasome and ribosome formation and the downregulation of the TNFα pathways, seems 
to describe a possible scenario where cell death is decreased and new cells maybe forming. On 
the other hand, cell cycle and DNA replication pathways were not found significantly changed 
in this group when compared to the cisplatin-treated animals. Interestingly, cell cycle was 
downregulated in the CM+ group, and so all the pathways involved in translation, transcription 
and replication.  
Based on gene expression analysis, it seems that the better results in terms of new cell formation 
was achieved by using the coCM+ treatment, while a reduction of inflammation was observed 
in both CM and coCM+ treated animals.  
 
miRNA analysis was also performed. Six differentially expressed miRNAs were found in CM+ 
(downregulated: miR-147, miR-155, miR-7a-1; upregulated: miR-5132, miR-196b, miR-
3594), 2 in CM (upregulated: miR-5132, miR-186) and 1 in coCM+ (downregulated: miR-142) 
and ivABCB5+ (upregulated: miR-6318). Five over 14 differentially expressed miRNAs found 
in the cisplatin-induced nephrotoxicity model were found oppositely regulated in animals 
treated with CM (miR-5132), coCM+ (miR-142) and CM+ (miR-5132, miR-196b, miR-147, 
miR-155) (Table 22). However, from the intersection of predicted miRNA target genes with 
differentially expressed genes only CM treated animals showed a sufficient number of genes to 
perform BP-GO analysis (Table 23). The analysis revealed the involvement of the 
downregulated miRNAs mostly in metabolic processes, cell growth and response to wounding 
(Table 24).  
 
We then questioned whether a possible different cytokine content in the three conditioned 
media could be the reason of the different gene expression results we observed. For this 
purpose, we checked for 12 cytokines (IL2, IL4, IL5, IL6, IL10, IL12, IL13, IL17A, IFNγ, 
 5. Discussion -81- 
 
 
 
 
 
TNFα, G-CSF, TGFβ1) that are known to be involved in inflammatory processes. As expected, 
we found some cytokines in coCM+ and M+. Indeed, it has already been known, that 
macrophages can synthetize and release a large variety of cytokines, which can be involved in 
several processes like immunity and homeostasis 135, 136.  We observed that in presence of 
ABCB5+ cells, stimulated macrophages produced less pro-inflammatory cytokine TNFα, 
indicating a possible presence of a M2 macrophage population (Figure 30). TGFβ1 and TNFα, 
predictably detected in M+, were found less abundant in coCM+, while IL-6 and G-CSF levels 
were found more than 10 times higher in coCM+ compared to all the other media. Excluding 
M+ and focusing on the three conditioned media administrated to the animals, we observe that 
coCM+ is the only medium in which TGFβ1, TNFα, IL-6 and G-CSF were found. We then 
questioned about the effects of these cytokines and whether they, once injected in the 
bloodstream of cisplatin-treated animals, could trigger any positive or negative response. As 
reported in literature, IL-6 is a pleiotropic cytokine that, depending on the situations, can have 
both anti-inflammatory and pro-inflammatory properties 137-139. Together with TNFα, IL-6 has 
been associated with muscle wasting and weight loss, which were indeed observed in the 
animals treated with coCM+ 140, 141. G-CSF is an immune modulator and a mobilizer of 
hematopoietic and mesenchymal stem cells from the bone marrow to the blood. Although the 
mechanism of action is still poorly understood, it is believed that, once in the bloodstream, the 
recruited stem cells could play a possible role in tissue recovery. Additionally, G-CSF has also 
been found to either modulate or exacerbate inflammatory processes depending on the context 
142, 143. TGFβ1 has been considered as an anti-inflammatory cytokine, even though more recent 
findings showed its involvement in the pro-inflammatory Th17 cell differentiation 144, 145. Under 
various circumstances, it can be either an anti-inflammatory or pro-inflammatory cytokine. 
Therefore, due to their pleiotropic potential, it is difficult to guess whether these cytokines can 
trigger a pro- or anti-inflammatory effect once injected into the cisplatin-treated animals. 
However, based on our transcriptomic data, we observed a higher anti- inflammatory effect in 
the coCM+ treated animals when compared to the other groups, indicating a possible 
involvement of these cytokines. 
 
 
In summary, this study describes the different outcomes obtained by treating cisplatin-induced 
nephrotoxicity with both ABCB5+ cells and derived conditioned media.  
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Regarding ABCB5+ cells treatment, we could demonstrate that the ip administration route 
could be a valid alternative to the classical and risky iv one. Although treatment with ABCB5+ 
cells did not show any functional amelioration. Neither of the two administration routes, ip 
injection of cells was able to promote important and more pronounced genetic changes in the 
renal tissue. Differently, conditioned media, and in particular CM, were able to induce some 
changes both at the functional and genetic level. coCM+ showed pronounced changes in the 
renal gene expression, but it failed in promoting amelioration in the plasma and urine 
parameters. Indeed, according to our results, CM displays the most pronounced therapeutic 
potential in treating cisplatin-induced nephrotoxicity, representing a promising approach. 
Certainly, further studies are necessary to investigate the modes of action involved and to 
optimize the therapeutic regimen to use for a possible translation to the clinical field. 
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6. Summary 
 
 
Kidney diseases are a global public health problem that lacks of effective therapies to prevent 
progressive loss of renal function after initial damage. Every year, we witness a continuous 
increase in the incidence of ESRD, for which the only available treatments are dialysis or renal 
transplantation. Being these two therapeutic options not only invasive for the patients, but also 
highly expensive for the public health system, new treatments are urgently required. In this 
scenario, stem cell therapy represents a promising approach for the treatment of renal injuries. 
Several studies have been conducted in this direction, but still no consensus has been achieved 
in terms of cell source, dose, timing and administration route to be used. In addition, the modes 
of action with which stem cells perform their therapeutic effects remain unclear and need further 
explanations. 
In this study, we established a well-defined animal model of cisplatin-induced kidney injury 
that was then used to assess the therapeutic potential of ABCB5+ cells and derived conditioned 
media. 
For the development of the animal model, we induced renal damage in immunocompetent SD 
rats by using a single ip injection of cisplatin, a well-known nephrotoxic drug, at the dose of 7 
mg/kg BW. The onset and progression of the disease has been characterized on the basis of 
plasma, urine and metabolic parameters, renal function transcutaneously measured, histological 
evaluation and both mRNA and miRNA expression profiling. The analyses performed indicated 
the successful establishment of a stable cisplatin-induced nephrotoxic model that was then used 
to assess the therapeutic potential of ABCB5+ cells and derived conditioned media. The 
following treatments have been tested: 1) ABCB5+ cells both iv and ip administrated; 2) 
ABCB5+ cells derived conditioned media iv administrated (CM, CM+, coCM+). 
The results showed that when animals were treated with ABCB5+ cells, we have not been able 
to see any amelioration in the plasma and urine parameters, renal function and histology and 
we did not observe any differences between the two applied administration routes. However, 
these animals did undergo genomic changes, which were even different in the two groups. 
Indeed, based on the gene expression analysis performed in renal tissue, it seems that the 
ipABCB5+ cell treatment triggered new cell formation and promoted a higher reduction of 
inflammation compared to the ivABCB5+ cell one. 
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In contrast, when three different conditioned media were administrated to the animals, we were 
able to see changes at the functional level. Indeed, markers of renal function, such as plasma 
creatinine and urea and urine albumin, were ameliorated especially after CM and CM+ 
treatments, while animals which received coCM+ did not show any deviation from the control 
animals. A similar trend was observed when the transcutaneous assessment of renal function 
was performed. Additionally, CM and CM+ treated animals did not lose appetite and therefore 
they did not show the typical loss of weight observed in the other experimental groups.  
However, at the genomic level, coCM+ treated group exhibited better results in terms of 
reduction of inflammation and new cell formation, showing some similarity with the 
ipABCB5+ cell treated group. Also in the CM treated group a reduction of inflammation was 
reported, while CM+ treated animals did not show any relevant changes when compared to the 
cisplatin-induced nephrotoxicity model. Additionally, BP-GO analysis of downregulated 
miRNAs found in CM treated animals, showed their involvement mostly in metabolic 
processes, cell growth and response to wounding.  
 
In conclusion, all together the results presented here demonstrate that CM displays the most 
pronounced therapeutic potential both at functional and genomic level in treating cisplatin-
induced nephrotoxicity. For a possible translation to the clinical field, further studies to 
optimize the therapeutic regimen and to elucidate the involved modes of action are needed.  
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